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The objective of this thesis was to investigate the various methodologies that can be 
applied for the selection and prioritization of compounds in drug discovery. The research 
work has been allocated into four parts, each catering to a different stage of the drug 
discovery process. 
 
In the first part of the thesis, the objective was to formulate a computational workflow 
that can be used to prioritize compounds of interest from a primary screen hit list for re-
confirmation screening, an important step in initiating lead discovery studies. A 
computational methodology based on the Random Forest Clustering (RFC) method that 
overcomes deficiencies of conventional techniques will be presented in this work. The 
successes of the RFC method in Triaging results from several in-house cell-based and 
enzymatic high-throughput screening datasets targeting dengue and tuberculosis will be 
presented. Challenges in extending the methodology to larger datasets and the mining for 
false negatives will also be discussed. 
 
In the second part of the thesis, the objective was to apply a particular frequent pattern 
mining technique to elucidate the substructures that are highly correlated to the good activity 
of compounds. The concept of Correlation Rules was applied with the aim of uncovering 
substructures that are not only well represented among known potent inhibitors but are also 
unrepresented among known inactive compounds and vice versa. Six selected kinases (2 each 






In the third part of the thesis, the objective was to identify small molecule compounds 
that are potential inhibitors of a particular therapeutic target in the search for a treatment for 
Dengue. The Dengue RNA-dependent RNA polymerase (RdRp) was chosen as the target 
since it is critical for the replication of the dengue virus’ RNA. In this work, a virtual 
screening workflow was formulated. A virtual screening protocol was formulated that 
included docking, pharmacophoric and shape based matching techniques for the analysis of 
the interactions of a corporate database against the enzymatic target. 
 
In the final part of the thesis, a novel application of the Taguchi Method which is an 
approach based on Design of Experiments (DoE), is used in lead optimization and SAR 
development of compounds. The results show that the Taguchi Method achieved favorable 
outcomes for biological activities that are measured against specific target proteins and 
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CHAPTER 1 INTRODUCTION TO COMPUTATIONAL METHODS 





Before work is started to discover any potential new medicine for a specific disease, 
scientists need to investigate the underlying cause of the disease as thoroughly as possible. In 
particular, they seek to understand how genes are altered and the related mechanism of action 
of the affected protein(s). After the underlying cause of the disease has been well understood, 
scientists will identify a “target” that can potentially interact with and be modulated by a drug 
molecule. This therapeutic target is typically a protein that has been validated thoroughly for 
its central role in the disease of interest. In the next phase, the objective is to find a promising 
molecule (often named the “lead compound”) that may act on their chosen target and has the 
potential to become a drug. Before the lead compound can be identified, however, a series of 
sourcing and screening activities must be carried out to discover a significant number of 
compounds that demonstrate the target’s activity. Such compounds are often called “hits”. 
The hits can come from a variety of sources including corporate archives, natural products, 
commercial compound libraries, high-throughput screening and even rational de novo design. 
The best hit compound will be promoted to lead compound status if it passes a series of tests 





which provide an early assessment of its safety. The next stage in the process is to alter the 
structure of the lead compound in order to improve its efficacy and safety profile. The result 
output is the optimized candidate drug. It will be subjected to extensive in vitro and in vivo 
testing to determine if it is safe enough for human testing. In the next step, the candidate drug 
enters the development process (clinical trials) in which it will be tested in humans for its 
efficacy and safety. Novel drug discovery and development is known to be lengthy, risky and 
costly. It takes around 14 years 
1
 and up to US$1.3 billion 
2
 from the conception phase to the 
market.  
 
Technologies such as combinatorial chemistry 
3, 4
 and high-throughput screening 
5, 6
 
were intended to speed up drug discovery significantly by synthesizing and screening huge 
compound libraries in a relatively short amount of time. However, despite such investments 
in the past few decades, drug discovery continues to suffer from low efficiency 
7
 and high 
failure rate. 
8
 Hence the emphasis has been on applying approaches that are able to expedite 
the drug discovery cycle, reduce financial expenditure and minimize risk of failure.  
 
Due to extensive improvements in information technology, computational methods are 
uniquely positioned as one of such approaches that may benefit the drug discovery process. 
9
 
Collectively, such computational methods are generally termed computer-aided drug design 
(CADD). Essentially, CADD comprise in silico tools specifically intended for organizing, 
modelling and analysis of chemical entities. Such tools are primarily concerned with 
designing novel compounds, 
10
 identifying the most probable lead candidates 
11-14
 and 
providing a deeper understanding of the protein-ligand interactions that are responsible for 










1.2 VIRTUAL SCREENING 
One of the essential aspects in CADD is virtual screening. Virtual screening 
18
 is the 
computational technique that deals with the rapid identification of the compounds of interest 
from a large compound library. The goal of virtual screening is to filter, score and rank 
structures of compounds using in silico methods. Virtual screening may be used to select and 
prioritize compounds for screening in assays, 
19
 selecting which compounds to acquire from a 
commercial supplier as well as which compounds to synthesize. 
20
 The techniques used in 
virtual screening are numerous and diverse. At the more basic level, general filtering 
techniques (such as substructure filters, 
21
 drug-like filters, 
22





) may be applied to remove compounds that do not meet the 
respective requirements. These filters assist in focusing the composition of a compound 
library towards those compounds with more desirable properties. However, virtual screening 
goes beyond such filtering techniques. 
 
In general, the various virtual screening approaches can be grouped into two broad 
categories: the ligand-based approach and the structure-based approach. If the three-
dimensional (3D) structure of the target macromolecule is not available, then the 
computational techniques will have to be based solely on the structural and biological activity 
data of known active compounds and/or inactive compounds. These ligand-based techniques 
include quantitative structure-activity relationship (QSAR), 
9, 25-27






 molecular field analysis 
31-35
 and 2D or 3D structural similarity matching. If the 3D 
structure of the potential target is available via crystal structure, nuclear magnetic resonance 
(NMR) 
36
 or homology models, 
37
 then the structure-based approach will be used. These 
techniques, such as molecular docking, are able to provide crucial insights into the type of 
interactions between drug targets and the ligands. 
 
 
1.3 MOLECULAR DOCKING & SCORING FUNCTIONS 
Molecular docking is commonly used to identify potential active compounds by 
ranking a library of compounds based on the strength of protein-ligand interactions which are 
evaluated via a scoring function. 
38, 39
 During the docking process, a search algorithm 
generates numerous different ligand orientations and conformations (collectively known as 
docked poses) in the binding pocket of the target macromolecule. 
40
 Molecular docking 
methods allow different levels of flexibility for the protein and ligands. It is commonplace for 
recent docking algorithms to allow complete flexibility for the ligands. To a lesser extent, 
different levels of flexibility to side chains of the amino acid residues in the binding pocket 
are allowed. In order to simulate the flexibility of the ligands, computational search 
algorithms have to be implemented. 
41
 The most exhaustive is the systemic search that 
iterates through every possible conformation along each dihedral in the ligand molecule. 
However, this is mostly impractical since there could be too many generated conformations 
that have to be docked and scored. Therefore, other alternatives have been investigated. 
42
 For 
example, the stochastic search algorithm generates conformations by introducing random 









  and GOLD 
45
 are molecular docking programs that use such random 
search algorithms.  
 
The other important aspect of molecular docking programs is the scoring function.
40, 46-
52
 A scoring function estimates the protein-ligand interaction energy of each docked pose. 
Theoretically, the docked pose with the best interaction energy is presumed to be the putative 
bioactive pose. However, the realities of applying the current scoring functions may limit the 
ability of molecular docking to accurately rank ligands based on the docking score. There are 




 and knowledge-based 
51, 62-
74
 scoring functions. Force field scoring functions uses molecular mechanics energy terms to 
calculate the internal energy and binding energy of the ligand. However, since it is 
computationally expensive to calculate the entropic terms, such terms are generally omitted 
during the calculations. A typical force field scoring function consists of the van der Waals 
term approximated by a Lennard Jones potential function 
75
 and an electrostatics term in the 
form of a Coulombic potential with distance-dependent dielectric function 
76
 to reduce the 
effect of charge-charge interactions. Empirical scoring functions are derived from fitting 
regression equations to known experimental data obtained from a number of protein-ligand 
complexes. Knowledge-based scoring functions are used to score simple pair-wise atom 
interactions based on their environment. 
62, 72-74
 The types of interactions that can exist are 
extracted from a set of known protein-ligand complexes. In order to reduce the dependency 
on any of these three types of scoring functions, the concept of consensus scoring 
77, 78
 was 
introduced. Typically, the different scoring functions are combined in a variety of ways so as 
to achieve improvement in the prediction of docked poses and binding affinity. 
77-87
 Despite 
the availability of all of these different types of scoring functions, the current state of the art 





associate free energy of binding. 
88
 This is because the existing scoring functions are merely 
simplified versions of the full protein-ligand interactions that neglect effects such as 
polarization and entropy. 
88
 Next, the strategies and concepts used in ligand-based approaches 
will be described.  
 
 
1.4 MOLECULAR SIMILARITY 
Molecular similarity 
89-99
 is a central concept in ligand-based approaches. The 
underlying assumption (Similar Property Principle) in molecular similarity is that structurally 
similar molecules are expected to possess similar modes of action or potency. 
100
 Typically, 
similarity search algorithms are used to seek out compounds of interest from a database of 
compounds. 
94
 The output of a similarity search often consists of a numerical score for every 
matching compound that is typically used to rank the outputs based on the level of similarity. 
The similarity score may also be used to discard those compounds that do not meet a 
similarity threshold. Although there are no formal definitions of molecular similarity, there 
are several ways to compare two or more molecules and thereafter quantitatively assess the 
level of similarity between them. 
91, 101
 Depending on whether the conformation information 
is taken into account, the similarity search algorithms can be categorised into 2D or 3D 
similarity searching. Usually, structural descriptors of the compounds have to be computed 
before any comparison is made. One example of such structural descriptors is molecular 
fingerprints. 
102
  Binary molecular fingerprints are derived from the 2D chemical structure 
and usually encode the presence or absence of sub-structural fragments. One well-known 
example is the MACCS fingerprints 
102
 (also known as the 166-bit MDL keys). In order to 





strings. A bit string is a vector of binary indices.  The extent of matching is compared 
quantitatively using the Tanimoto coefficient. 
103
 The value of the Tanimoto coefficient 
ranges from zero (no bits in common) to one. However, the value of one does not confirm 
that the compounds are identical but that they merely have identical fingerprint 
representations. 
 
Recently, the underlying assumption that structurally similar molecules possess similar 
potencies has been challenged by the concept of activity cliffs. 
104
 An activity cliff is defined 
as a pair of molecules that are structurally very similar but display large differences in 
potency.  Martin Yvonne et al reported that for IC50 values determined as a follow-up to 115 
high-throughput screening assays, there is only a 30% chance that a compound that is ≥ 0.85 
(Tanimoto) similar to an active is itself active. 
105
 This is because similar compounds do not 
necessarily interact with the target macromolecule in similar ways. However, activity cliffs 
may not be such a detrimental phenomenon in the context of drug discovery. Guha and Van 
Drie quantified activity cliffs by defining the Structure-Activity Landscape Index (SALI). 
106
 
High SALI values indicate steep activity cliffs in a dataset. For the purposes of drug design, 
these are possibly the regions that may be exploited for significantly improving biological 
activities by making minor pair-wise structural modifications to molecules.  
 
Molecular similarity has moved beyond the traditional confines of structural similarity. 
It is now possible to compare molecules based on 3D molecular fields. 
31-35
 In that approach, 
four molecular fields are calculated to represent the binding properties of a molecule. They 
are: positive electrostatic, negative electrostatic, van der Waals and hydrophobic. These are 





the 3D surface of the molecule. 
35
 Thereafter, field points are placed at the spatial location of 
the local maxima of each of the first three above-mentioned properties. For the hydrophobic 
property, the field point is placed at the centre of the hydrophobic groups instead. These field 
points identify the spatial locations where the binding interactions are likely to be the most 
intense. As such, these field points are effectively analogous to pharmacophore features in a 
classical pharmacophore model. 
31
 The spatial arrangements of the field points can therefore 
be use to screen for compounds that exhibit similar spatial molecule field points even if they 
are structurally dissimilar. Therefore, the 3D molecular fields technique may enable either 
replacing a functional group possessing undesirable liabilities (isostere) or changing to a 




Apart from structural similarity and molecular fields, molecular similarity can also be 
determined via molecular shape comparison. 
11, 107-112
 There are several shape comparison 
methods. One such example is Rapid Overlay of Chemical Structures (ROCS). 
110
 For ROCS, 
molecules that have significant overlaps in their volumes are determined to have similar 
shape. The concept of molecular shape, as implemented in ROCS, is represented as a 
continuous function constructed from atom-centred Gaussian functions. The main use of 
ROCS is for scaffold hopping from a query molecule to other molecules with similar 3D 
shapes but with low 2D structural similarity to the query molecule. The other example of 
molecular shape comparison algorithms is the method named Ultrafast Shape Recognition 
(USR). 
11
 It is an alignment-free method, i.e. it does not require that the molecules being 
compared to be superimposed spatially. USR determines molecular shape moments based on 
the following points within a molecule: the centroid, the closest atom to the centroid, the 
furthest atom from the centroid and the furthest atom from the furthest atom from the 







Another 3D ligand-based approach is pharmacophore mapping. 
113-130
 A 
pharmacophore is a spatial (3D) arrangement of atoms or structural features that impart a 
particular pharmacological or biological activity to a molecule. The goal of pharmacophore 
mapping is to discover 3D patterns present in different compounds that share a proximal 
spatial location. 
118-120
 Typically, a pharmacophore is mapped from conformational ensembles 
of compounds with known activities. In the first step, the preferred conformations of the 
compounds are derived via a conformational search. Next, the common groups are defined in 
terms of specific atom types, surfaces with a certain charge property, functional groups or 
some other shared property. Thereafter, the 3D conformation of compounds are spatially 
aligned and superimposed at the specific points in a defined way. Finally, the pharmacophore 
is elucidated by joining the sites in common. Typically, there are at least three 
pharmacophore features that serve as connection points. Often, pharmacophores are used as 
3D queries for searching compound databases. 
116
 Pharmacophores are generally proposed if 
the 3D structure of the therapeutic target is not available. 
122
 In such a scenario, they can be 
used to suggest possible features of the binding site on the target macromolecule. However, 
pharmacophores have an underlying assumption that the compounds interact with the same 










The molecular similarity concept has been discussed above in the context of matching 
structures at the molecular level. However, it can also be applied to sub-structural fragments 
of molecules. A substructure search is a widely used approach to select compounds of interest 
from a database of molecules. 
21, 131-133
 Such a search seeks to identify all the molecules in the 
database that possess the substructure used as the query. The substructure may be a specific 
sequence of atoms or a functional group. 
134
 Methods based on graph theory can be used to 
perform a substructure search. 
135
 Graph theoretic methods determine the solution to the 
subgraph isomorphism problem. 
136
 In other words, it determines whether one graph 
(analogous to a specific substructure) is completely contained within another (analogous to a 
molecule). However, the subgraph isomorphism search belongs to the NP-complete class of 
problems (NP: Non-deterministic Polynomial time). 
137
 A NP-complete problem is a 
computational problem that cannot be solved in polynomial time, i.e. it is not solvable in a 
realistic timeframe. 
138
 In order to find a solution, the amount of time it requires increases 
exponentially with the number of nodes in the graph (analogous to the number of atoms). 
Fortunately, there are heuristics-based methods that are more efficient. The Ullmann 
algorithm is one such widely used method. 
139
 The molecular graphs of the query substructure 
and the database molecule are represented using adjacency matrices. The rows and columns 
in an adjacency matrix correspond to the atoms in the structure. The elements (i, j) and (j, i) 
of the matrix will be assigned the value of “1” if atoms i and j are bonded and the value of “0” 
otherwise. The adjacency matrix S represents the query substructure and the adjacency matrix 
M corresponds to the database molecule. Another matrix A is then constructed such that the 
rows correspond to the query substructures and the columns correspond to the atoms of the 
database molecule. If there is a match between particular pairs of atoms, then the 
corresponding element in matrix A will be assigned the value of “1” and “0” otherwise. The 





contains only one element assigned the value of “1” and each row contains just one element 
is assigned the value of “1”. Molecular similarity not only allow searches to be carried out to 
identify similar molecules, the concept of similarity can be further leveraged upon via 
computational algorithms to predict the properties of molecules based on retrospective 
information of molecules with known properties. 
 
 
1.7 MACHINE LEARNING IN VIRTUAL SCREENING 
Apart from the above-mentioned approaches, another common way in which 
computational methods can support the drug discovery process is the application of pattern 
recognition and machine learning algorithms to the analysis of large datasets that are 
generated by high throughput screening of compound libraries. The proper application of 
such algorithms is particularly useful in guiding the medicinal chemists in compound library 
design and hit identification. 
140, 141
 The primary goal of machine learning 
140-156
 is to extract 
knowledge from raw data. Machine learning algorithms can be categorised into unsupervised 
and supervised learning. 
157
 For unsupervised learning algorithms, the objective is to 
segregate or group similar data points by extracting the trends and patterns within the input 
data. 
158
 One common example of unsupervised learning is clustering. Clustering 
159
 can be 
divided into hierarchical methods and non-hierarchical methods. Hierarchical methods are 
further divided into divisive and agglomerative clustering. 
160
 Divisive methods begin with all 
the compounds which are subsequently divided into finer clusters whereas agglomerative 
techniques begin with a single compound and build up the cluster by including more 
compounds iteratively. 
161
 Such methods are termed hierarchical because the contents of each 





approaches segregate compounds into a specific number of clusters that have been pre-
defined by the user. 
162
 Typically, the compounds that are nearest to one another in chemical 
space are clustered together. The compounds are generally represented as vectors of 
descriptors and the distances between these vectors can be computed. A vector that occupies 
a central position and thus distinguishes itself from the other clusters is then chosen as the 
centre for that particular cluster. The rest of the vectors are assigned accordingly to the 
nearest cluster centre in descriptor space. Jarvis-Patrick clustering 
163
 is one such nearest 
neighbour method. Two compounds are assigned to the same cluster if they share a pre-
defined minimum number of nearest neighbours. The other non-hierarchical clustering 
method is k-means clustering. 
164
 In this method, k clusters are randomly seeded, cluster 
means are computed and compounds are re-allocated to other clusters if their positions are 
closer to those means as compared to the one of their initial cluster. The choice of the value 




Supervised machine learning methods use a training set of items that have previously 
been classified into two or more classes as inputs. For example, a collection of molecules that 
have been experimentally characterised as active or inactive is used as training-set molecules. 
They are analysed to elucidate a decision boundary or rule that is used to classify test-set 
(previously unseen) molecules into one of the classes known in the training-set molecules. 
Such supervised learning techniques are also known as classification algorithms. They can 
therefore be used to predict a novel molecule’s biological activity before experimental assay 
is actually carried out. In this way, molecules with the best predicted activity may be 
prioritised before the actual biological testing. 
141, 145, 146, 153
 The various approaches that have 
been used to classify molecular data include neural networks, 
166, 167
 support vector machines, 
150, 168-174
 decision trees 
175







1.8 STATEMENT OF PURPOSE 
The research work conducted for this thesis has been allocated into four parts, each 
with an objective catering to a different stage of the drug discovery process. The various 
computational techniques reviewed in the previous sections were applied to the work 
described in this thesis.  
 
The objective of first part of the thesis is to formulate a computational workflow that 
can be used to prioritize compounds of interest from a primary screen hit list for re-
confirmation screening which is an important step in initiating lead discovery studies. 
Primary screen results from High Throughput Screening (HTS) of compound libraries are 
often skewed and noisy. Consequently, triaging these hit lists is challenging. Commonly used 
methods such as selecting compounds by imposing cut-off values on primary screen activity 
data and the “mean + 3 standard deviations” method are not able to handle the skewed results 
adequately. They either involve selecting a subjective cut-off value or assuming that the 
primary screen results have a Gaussian distribution which may not be true. Thus far, 
computational techniques have not been extensively applied to mine primary screen results 
for true actives. A computational methodology of hit list triaging based on the Random Forest 
Clustering (RFC) method was investigated for its capacity to address some of the deficiencies 
of the earlier mentioned methods. The method will be used to triage in-house cell-based and 
enzymatic HTS datasets targeting dengue and tuberculosis. The aim is to show that RFC 
accurately identifies a large percentage of the true actives and to demonstrate that it 






Compounds known to be potent against a specific protein target may potentially 
contain a signature profile of common substructures that is highly correlated to their potency. 
These substructure profiles may be used to enrich compound libraries or to prioritize 
compounds against a specific protein target. With this objective in mind, a set of compounds 
with known potency against six selected kinases (2 each from 3 kinase families) will be used 
to generate binary molecular fingerprints. Each fingerprint key represents a substructure that 
is found within a compound and the frequency with which the fingerprint occurs is tabulated. 
Thereafter, the concept of Correlation Rules will be applied with the aim of uncovering 
substructures that are not only well represented among known potent inhibitors but also 
unrepresented among known inactive compounds and vice versa. Substructure profiles that 
should be representative of potent inhibitors against each of the 3 kinase families will thus be 
extracted. By conducting five-fold cross-validation, these substructure profiles will be 
investigated to determine if they have a significant presence in highly potent compounds 
against their respective kinase targets. The advantages of using Correlation Rules over 
Association Rules in analyzing such datasets and the methodology used in the mining of 
enriching substructures will also be investigated.  
 
The dengue RNA-dependent RNA polymerase (RdRp) plays a critical role in the 
replication of dengue viral RNA and is hence an attractive therapeutic target. In the third part 
of this thesis, the objective is to identify non-nucleoside compounds that are potential 
inhibitors of the dengue RdRp using virtual screening workflows. An in-house crystal 
structure of a compound bound to an allosteric binding pocket of RdRp will be used for 
mining small-molecule libraries based on shape and electrostatics matching methods. Further, 
a pharmacophore will be generated from the analogues of the crystal compound and their 





list in order to identify compounds that possess the key features important for the allosteric 
binding. 
 
The resources and time required for the systematic exploration of the full SAR 
landscape are often overwhelming and thus not practical. Therefore, in the final part of this 
thesis, a novel application of the Taguchi Method as an objective approach to the 
optimization of chemical modifications to a core structure will be attempted. The Taguchi 
Method, an approach based on Design of Experiments (DoE), is widely used in the 
manufacturing industry for quality engineering purposes. In DoE, a design matrix is 
constructed in a combinatorial fashion that specifies the levels for several different factors for 
each experiment. In our context, these factors are the substituent functional groups. Each 
designed experiment is therefore a compound to be synthesized and is a combination of the 
defined levels of each factor. The biological activities of these molecules will be determined 
experimentally and analyzed thereafter. The optimal levels for each factor will be combined 
to form a new set of molecules that will hopefully exhibit more potent activity. If successful, 
this efficient approach tests all factors with comparatively fewer molecules and therefore may 










The screening of compound libraries from a pharmaceutical company’s collection or 
commercially available compounds is now commonplace. These collections usually contain 
millions of compounds. The objective of any screening program is to identify suitable hits 
that can be channelled down the drug discovery pipeline. Figure 2.1 illustrates a typical 
workflow of compound selection and screening in the pharmaceutical industry. Once the 
biological assay has been developed and suitably scaled up for high-throughput screening, a 
compound library is tested on this assay in what is known as the primary screen. Usually, in 
the primary screen, all compounds are tested at one concentration. The output is a hit list: a 
list of compounds and their corresponding percentage activity values (e.g. % inhibition). 
Typically, only a subset of compounds in the hit list will be selected for re-confirmation 
screening. The process of selecting and prioritizing compounds from the primary screen hit 
list is known as triaging. The reconfirmation screen will elucidate the dose-response values of 
each compound and only compounds with reasonable dose-response activities and Hill Slope 
values are shortlisted as Confirmed Hits. Confirmed Hits are generally used as starting points 
to screen the company’s compound archives for similar compounds in order to further 
explore structure-activity relationships (SARs) and develop a more complete picture of the 
chemical space available to a particular hit. This process is the first step in identifying reliable 






Figure 2.1 Typical workflow of compound selection and screening in the pharmaceutical industry. 
 
Together with an increase in screening throughput, a significant amount of assay data 
is typically generated in parallel. 
178
 However, automations in the initial phase of hit 
identification require considerable investments in the storage, retrieval and interpretation of 
the data into useful information. As such, the application of data mining methods to analyse 
these data will guide the medicinal chemist in the hit identification step, structural 
optimization based on a particular chemical scaffold or the optimization of compound library 
design. 
179-182
 Typically, such knowledge can be derived from the recognition of patterns or 
trends using computational methods based on machine learning and data mining. 
 
Previous work pertaining to the analysis of high-throughput screening data will be 
reviewed here briefly. Varin, et al., devised a new method (called Compound Set Enrichment) 
to identify active chemical series from primary screening data. 
183





scaffold tree compound classification in conjunction with the Kolmogorov-Smirnov statistic 
to assess the overall activity of a compound scaffold. They demonstrated that Compound Set 
Enrichment is able to identify compound classes with only weakly active compounds 
(potentially latent hits). Swamidass and co-workers investigated an economic framework to 
prioritize confirmatory tests after a high-throughput screen. 
184
 The method was shown to be 
able yield an economically optimal experimental strategy for deciding the number of hits to 
confirm and the marginal cost of discovery. They also identified 157 additional actives that 
had been erroneously labelled inactive in one screening experiment. Gubler, et al., 
investigated the possible causes of the typically poor correlation between percent inhibition 
values and IC50 values observed in high throughput screening. 
185
 They found out that the 
typical variations of the actual compound concentrations in existing screening libraries 
generate the largest contributions to imperfect correlations. 
 
Machine learning techniques are organized into two main types: supervised learning 
and unsupervised learning. Supervised learning involves the deduction of a function from 
training data. The training data typically consist of vectors of input variables describing 
properties (descriptors) of each item in the dataset as well as the known class label or 
category that the item belongs to. The function deduced from the training data is able to 
predict a class label of a previously unseen item in a process known as classification. 
Essentially, a supervised learning method predicts the class label of an unseen item based on 
the generalizations formed from the training data. In contrast, unsupervised learning 
determines how the items in a dataset are organized based on unlabeled input items and their 
corresponding descriptors. One form of unsupervised learning is clustering. It is the 





similar based on distance measures. Distance measures determine the similarity between two 
items.  
Decision trees are commonly used in data mining (the process of extracting patterns 
from data) and machine learning. The objective of a decision tree is to create a predictive 
model that maps descriptors of an item to the item’s target value. Each decision tree consists 
of nodes, branches and leaves. Each node corresponds to one of the descriptors and branching 
of the node to give “children” nodes provides the possible values of that descriptor. Each leaf 
represents the target value given the values of the descriptors represented by the path from 
the root to the leaf. When a dataset of descriptors is read into a decision tree, the tree 
essentially splits the dataset into subsets based on an attribute value test. Each of the derived 
subsets is further split in a recursive manner (recursive partitioning). The splitting stops when 
the subset at a node achieve the same target value or when terminal nodes are too small or too 
few to be split further.  
 
In data mining, when the predicted outcome of a decision tree is the class to which the 
items belong, it is termed a classification tree. A Random Forest classifier (RF) uses a 
number of such binary classification trees, thereby forming a ‘forest’, in order to improve the 
classification accuracy. RF is trained in a supervised manner. Training involves tree 
construction as well as assigning to each leaf node the class labels stipulated in the training 
samples for each input item reaching that particular leaf node. After the training is completed, 
an unseen test sample is passed down all the pre-constructed trees in the ‘forest’, and the 
output is computed by averaging the distributions recorded at the reached leaf nodes. The 
randomization of RF is achieved by training each tree on a random subset of the training data 





Among this random subset, the training procedure picks the binary test that splits the training 
samples in the optimal way. RF has seen only limited application in compound selection and 
prioritization.  
 
Figure 2.2 Idealised Gaussian distribution and an indication of the top X% of compounds (area under curve). 
 
Figure 2.3 Idealised Gaussian distribution and an indication of n percent inhibition cut-off. 
 
The current approaches of triaging primary data sets and their associated disadvantages 
are as follows: 
 Retain an arbitrary top X % of the compounds or  
 Choose compounds with > n% inhibition values.20 
In the first step, the decision is made as to what is the cut-off % inhibition value of the 





complete hit list is set as the threshold value (Figure 2.3). Next, these values are applied to 
the hit list and compounds that exceed these values are sent for reconfirmation screens. 
The fundamental disadvantage of this approach is that cut-off values are arbitrarily 
determined and thus admittedly subjective.  
 Retain compounds whose activities (e.g. % inhibition) exceed the “+3” threshold. 
This approach involves first determining the mean (µ) and standard deviation (σ) of the 
primary screen percentage inhibition data. Thereafter, only compounds with % inhibition 
greater than µ+3σ value are sent for reconfirmation screening. If the distribution is 
Gaussian, then the method will select the top 0.13% of the hits for reconfirmation 
screening. If the distribution is not Gaussian, then the skewness (a measure of asymmetry) 
of the distribution will determine the proportion of compounds selected for further testing. 
In the case where the distribution is positively skewed (wherein the right tail is longer and 
the bulk of the distribution is concentrated on the left), it will have a lower corresponding 
mean value and this would affect the value of µ+3σ. In other words, this approach is 
applicable only if the assumption that the distribution of the primary screen data is 
Gaussian (normal) is valid. Moreover, if there are a large number of compounds in the 
distribution, even the µ+3σ cut-off would select too many compounds for the 
reconfirmation screen. However, despite its deficiencies, the “µ+3σ” approach is widely 
applied in the pharmaceutical industry. 
 Cluster and retain from each cluster a limited number of representatives. 
In this approach, all the compounds in the hit list are assigned into various clusters 
according to various ways of measuring the similarity between compounds (e.g. molecular 
fingerprints based on chemical structures). After the clustering, only ‘representative’ 





approach is that similar compounds will exhibit similar biological activities which may not 
be necessarily correct. There may be compounds in each cluster which were omitted from 
the reconfirmation screen but are biologically active (false negatives). 
  
 There is therefore a need to formulate a novel method of selecting and prioritizing 
compounds from a primary screen hit list. If a reliable computational workflow is formulated, 
the accuracy of hit list triaging may be improved and this would in turn expedite the 
discovery of lead compounds in drug discovery projects. 
 
The computational workflow to be formulated requires a benchmark method that 
can be used for comparison. The possibility of using the “retain top x%” as the benchmark 
was considered carefully. However, one issue of concern is that the “retain top x%” 
method does not take into account the skewness of the data distribution. The skewness of 
the distribution may inherently contain implicit information regarding the experimental 
conditions of the HTS assay. All these will be lost if the “retain top x%” method is applied 
as the benchmark method.  
 
The concern is that the method requires an arbitrary value of x to be set. There is no 
consensus in practice or in literature of what the value of x should be. Another possible 
difficulty in applying the “retain top x%” method as the benchmark is that for different 
datasets, should the value of x be different or kept at a constant value? The ability of the 
“retain top x%” method to identify actives thus has the potential to become inconsistent 





number of actives selected. Therefore, the +3 method is still the de facto choice in the 
industry. It provides a consistent method that can be applied across datasets. 
 
2.2 MATERIALS AND METHODS 
2.2.1 DATASETS 
Table 2.1 Datasets used in the analysis and the corresponding assay systems. 




ATP Synthase vesicular 
assay 
ATPSyn.Prestwick 1120 





Dengue RNA dependent 




The ATPSyn.Prestwick dataset comprises 1120 compounds from the commercial 
Prestwick Chemical Library tested in the ATP Synthase vesicular assay. Ninety percent of the 
compounds in this library are marketed drugs and ten percent are bioactive alkaloids or 
related substances. The same library was used in the cell-based screen on the Bacillus 
Calmette-Guérin strain and this is the BCG.Prestwick dataset. The Dg.Lib2009 dataset 
comprises 436 hits from a screen against dengue RdRp using an in-house compound library 
named Lib2009. This library consists of 40481 compounds that have been extracted from the 
Novartis company archive collection by excluding compounds that contain reactive 
functional groups, toxicophores as well as other structural filters. The Dg.Lib2010 dataset 





library named Lib2010. This library was also extracted from the company archive collection 
using the same exclusion criteria and structural filters. 
 
2.2.2 PRE-PROCESSING 
Chemical structures of all the compounds in the libraries investigated were first energy 
minimized in Molecular Operating Environment 
186
 MOE (forcefield: MMFF94x, Root Mean 
Square Gradient: 0.05). Consequently, they were converted from flat two-dimensional 
structures to three-dimensional energy-minimized structures. Thereafter, 307 descriptors were 
computed using MOE for the compounds and stored in a MOE Database. Out of these 
descriptors, 14 descriptors (Table 2.2) were selected for Random Forest Clustering based on 
the ATPSyn.Prestwick dataset. 
Table 2.2 Fourteen descriptors selected for use in the analysis. 
Descriptors Description 
b_rotN Number of rotatable bonds 
chiral Number of chiral centers 
E Value of the potential energy 
E_rvdw Van der Waals interaction energy  
mr Molar refractivity 
reactive Presence of reactive groups 
rings Number of rings 
a_acc Number of H-bond acceptor atoms  
a_don Number of H-bond donor atoms  
a_hyd Number of hydrophobic atoms  
KierFlex Molecular flexibility index 





vdw_area VDW surface area 
Weight Molecular weight 
 
 
2.2.3 DECISION STUMP 
Packages of the statistical programming environment R (http://www.r-project.org) were 
used in the following analysis. Initially, the tree package was used to generate a decision tree 
in order to elucidate: 
1. The most important factor or descriptor which affects the primary screen activity 
values. 
2. The internal partitioning of the dataset into those with higher mean primary screen 
activity value and those with lower mean activity value.  
The tree was grown by binary recursive partitioning using the primary screen activity values 
and choosing splits from the descriptor values. Numeric descriptors are divided into X<a and 
X>a. Each split maximises the reduction in impurity of the child nodes. Splitting continues 
until the terminal nodes are too small or too few to be split. 
The output of this process, using the ATPSyn.Prestwick Library, is a decision tree: 
However, for the two purposes stated above, it is sufficient to just use the 2 partitions 
after the first split node and ignore the rest of the levels below. Such a single-level decision 
tree is known as a decision stump. Therefore, based on the decision stump, the descriptor 
logP(o/w) (Log of the octanol/water partition coefficient) is the most important factor which 
separates the Prestwick Library dataset into 2 partitions, one with compounds associated with 






2.2.4 RANDOM FOREST CLUSTERING 
In the event that the decision stump failed to partition the dataset in the manner 
described above, Random Forest Clustering (RFC) was applied. 
187
 RFC was originally used 
for tissue microarray data analysis. It differs from the original Random Forest classifier (RF) 
in that RFC is unsupervised which means that it does not require any training sets (containing 
known actives and inactive compounds as examples). Consequently, this method is ideally 
suited for the purpose of this work where no arbitrary pre-determined cut-offs has been set. In 
fact, no known actives are available for inclusion into the training set since the therapeutic 
targets are novel. 
The following paragraph summarizes the workflow in RFC:  
The values of the 14 descriptors (Table 2.2) for each compound are collated and 
converted into a vector of descriptors. Hence the input from the library of compounds into 
RFC is a matrix of descriptors with each compound represented as a vector. This matrix of 
descriptors is labelled internally as Class 1. Next, RFC randomly samples from the univariate 
distributions of the descriptors to create new vectors of synthetic ‘descriptors’. Synthetic data 
are added by randomly sampling from the hyper-rectangle that contains the observed data, i.e. 
the variables of synthetic observations have a uniform distribution with range determined by 
the minimum and maximum of the corresponding observed descriptor. This matrix of 
synthetic vectors is labelled internally as Class 2. Subsequently, the Random Forest classifier 
uses Class 1 and Class 2 as training sets in a supervised machine learning approach to 
generate a similarity score for each compound. The similarity scores of Class 1 are collated 
into a matrix and it is then mathematically transformed into a dissimilarity matrix. This 





(PAM). The PAM algorithm first computes k representative objects, called mediods or 
median points. A mediod is a data point (compound), whose average dissimilarity to all the 
other data points (compounds) is minimal. After finding the set of mediods, each compound 
is assigned to the nearest mediod. The PAM is an unsupervised clustering method and this is 
how the Random Forest classifier is adapted from a supervised method into the unsupervised 
method RFC. When applying RFC to this work, the number of clusters required is set to 2. 
 
The putative ‘actives’ predicted by RFC are then binned according to their 
corresponding primary screen activity values in a frequency histogram. The compounds are 
selected to be sent for reconfirmation screening in sets, each bin constituting one set. Bins are 
selected in descending order of percentage inhibition. Compounds that demonstrate definitive 
dose-response activities in the reconfirmation screens are known as confirmed hits. 
 
2.2.5 DESCRIPTOR SELECTION 
The machine learning method used (RFC) in this work is an unsupervised method. 
Such methods do not have the availability of known outcomes to assess and refine the 
selection of descriptors used. On the contrary, supervised methods use known outcomes to 
guide descriptor selection in an iterative, retrospective manner. Hence the descriptor selection 
procedures for supervised methods are comparatively more straightforward compared to 
those for unsupervised methods. Therefore, for the purposes of this work, the best option will 
be to make use of the internal structure of the entire descriptor set or parts thereof for the 
descriptor selection procedure. Although 14 descriptors have been selected based on the 





selection procedure should be able to adapt dynamically according to the different datasets 
used. 
 
As mentioned above, the internal structure of the descriptor set could be used for the 
descriptor selection procedure. Therefore, it is important to be aware that this procedure 
should be focussed on selecting a subset of appropriate descriptors under the constraint of not 
knowing which molecules will be re-confirmed as true actives. Hence that is the context of 
the scientific problem that the descriptor selection procedure will attempt to overcome.  
While the chosen procedure may be applied to other feature selection problems, such 
applicability is outside the scope of this thesis. Henceforth, the issue to be investigated will 
be which properties of the internal structure of the descriptor set should be explored to 
achieve the purpose. Several properties that may be of interest are: 
1. The level of clustering that each descriptor exhibits 
Descriptors that are clustered demonstrate that they are able to segregate in the respective 
descriptor spaces. Randomly distributed descriptors are potentially less interesting since 
their random distribution cannot be leveraged upon so readily.  
2. The skewness of each descriptor. 
Evenly distributed descriptors are theoretically less attractive. If a particular descriptor is 
evenly distributed, there is no segregation in the descriptor’s space. Therefore, it is 
unlikely that the descriptor will be useful in separating compounds during clustering. 





Sparsely clustered descriptors are possibly of less value. If a particular descriptor is 
sparsely clustered, it indicates that there is no strong segregation of compounds in that 
space. Therefore, it is unlikely to be useful in the clustering of compounds.  
In order to explore the usefulness of the properties of interest listed above in formulating the 
descriptor selection procedure, the following 3 scores were generated for each molecular 
descriptor: 
 Hopkins Statistic 188 
The Hopkins Statistic 
188
 is a measure of clustering tendency. It examines whether 
objects in a dataset are uniformly distributed in a multi-dimensional space. It can be 
calculated using the following steps: 
Step 1: Calculate the Euclidean distances (dsn) between M experimental objects (s) 
and their nearest experimental neighbours/objects (n). Sum up these distances. 
Step 2: Generate uniformly distributed (regularly spaced) artificial objects. 
Step 3: Calculate the Euclidean distances (drs) between M artificial objects (r) and 
their nearest experimental neighbours/objects (s). Sum up these distances. 
Step 4: Calculate the Hopkins Statistic by dividing the respective summed distances 
according to the following formula: 
  
      
 
   
      
 
          
 
   
 
o h should be >> 0.5 ( ≈ 1.0) for very well-defined tightly clustered data since 





      
 
    will be very small relative to the total distances from those of 
artificial objects to the experimental objects       
 
   .  
o h should be ≤ 0.5 for non-clustered (regularly spaced) data since the distance 
from one experimental object to another experimental object       
 
    will 
be approximately the same, on average, as the distance from a uniformly 
distributed artificial object to one of the experimental objects       
 
   . 
 Skewness 
It is the degree of departure from the symmetry of a distribution. The larger the value 
of the skewness, the more suitable a particular descriptor is for clustering compounds.  
 Kurtosis 
It is the degree of peakedness of a distribution. The larger the value of kurtosis, the 
more “pointed” the distribution. Molecular descriptors with large kurtosis values 
indicate that they are clustered in a compact manner and are therefore preferred 
during descriptor selection. 
 For a descriptor to be selected, the following criteria were investigated: 
 h was > 0.5 and highest 20%. 
 Skewness was the highest 20%. 
 Kurtosis was the highest 20%. 
Only descriptors that satisfy the above 3 criteria are retained while others that do not comply 
with the criteria are rejected. The aim was to investigate whether these criteria could serve as 
a set of filters for selecting a subset of appropriate molecular descriptors within the context of 







2.3 RESULTS AND DISCUSSION 
Each of the datasets in Table 2.1 was analyzed in turn. The ATPSyn.Prestwick set was 
analyzed first using the hand-picked 14 descriptors. 
 
2.3.1 PERFORMANCE OF RANDOM FOREST CLUSTERING, DECISION 
STUMP VERSUS µ+3σ METHOD USING 14 DESCRIPTORS 
 
As shown in Figure 2.4, the distribution of the primary screen activity data (brown 
bars) of the ATPSyn.Prestwick Library against the ATP synthase of Mycobacterium 
tuberculosis is positively skewed. The bins of putative ‘actives’ predicted by RFC are shown 
in orange, those of the putative ‘actives’ predicted by Decision Stump are shown in yellow. 
Interestingly, most of the trimmings by RFC are in the bins with less than 30% inhibition. 
Although the yellow bars (by Decision Stump) are even shorter in the bins with less than 30% 
inhibition, the yellow bars are also trimmed in the > 70% inhibition range. However, the 






Figure 2.4 Frequency histogram showing the ATPSyn.Prestwick percentage inhibition data from three sources: 
the original dataset from the primary without any treatment by data mining methods (Before treatment), the 
putative ‘actives’ as predicted by RFC (coloured orange), those predicted by Decision Stump (coloured yellow). 
This dataset exhibits a positive skew (non-Gaussian). 
 
 
Table 2.3 Descriptive statistics of the ATPSyn.Prestwick dataset. 
ATPSyn.Prestwick Dataset 
Mean percentage inhibition, µ 16.91% 
Standard deviation, σ 27.03% 
µ+3σ 98.00% 
Maximum percentage inhibition 101.34% 
Minimum percentage inhibition 40.24% 
 
According to reconfirmation screening results (IC50), all 8 compounds in the 110% 
inhibition bin were confirmed hits (Figure 2.5a). The RFC also predicted these compounds as 
actives but Decision Stump predicted one of the compounds with IC50 < 6µM to be inactive. 





























The RFC predicted 31 compounds as actives besides correctly predicted the inactive 
compound. The Decision Stump predicted only 25 compounds as active and incorrectly 
predicted the inactive compound as active. The Decision Stump also incorrectly predicted 5 
compounds with IC50 less than 6µM as inactive. In the 90% inhibition bin, all 8 compounds 
were confirmed hits (Figure 2.5c). The RFC correctly predicted all 8 compounds as actives 
but Decision Stump incorrectly predicted two of the compounds with IC50 < 10µM to be 
inactive. In total, if the compounds to be sent for reconfirmation screening were based on the 
3 bins with highest percentage inhibition, Decision Stump would have missed 8 compounds 
with IC50 less than 10µM. In comparison, RFC would have missed only 1 compound. 
 
In order to verify that RFC outperforms the µ+3σ method, the histogram in Figure 2.6 
compares the number of compounds which have been selected by both methods respectively. 
From the histogram it is clear that RFC correctly predicted 47 out of 49 confirmed hits while 
the µ+3σ method predicted only 41 of the confirmed hits (83.6%). For this dataset, the µ+3σ 
method had selected only compounds with percentage inhibition more than 98.0% (Table 2.3) 
for reconfirmation screening, i.e. some of the actives which were later reconfirmed to have 
low IC50 values for reconfirmed activities would not have been identified. More importantly, 
the dose-response results from the reconfirmation screen show that RFC correctly picked 96% 
of the confirmed hits. Therefore, the RFC method has marginally outperformed the current de 
facto µ+3σ method. 
 
It was decided to investigate the convergence properties of the RFC methodology with 
respect to the number of trees and the effect of the truncations on the quality of the results 





desktop computer using a compound library of 1120 compounds and various settings for the 
number of trees are listed below: 
• 4000 trees: >8 hrs 
•  400 trees: 3 hrs 
•  4 trees: 0.2 hrs  
































































































Figure 2.5 Frequency histogram showing the number of compounds selected using various methods from a) the 






































Figure 2.7 Frequency histogram showing the Dg.Lib2009 percentage inhibition data without any treatment. 





















Bins (% inhibition) 
Dg.Lib2009 Dataset 





Table 2.4 Descriptive statistics of the Dg.Lib2009 dataset. 
Dg.Lib2009 Dataset 
Mean percentage inhibition, µ 52.00% 
Standard deviation, σ 17.68% 
µ+3σ 105.04% 
Maximum percentage inhibition 100.23% 
Minimum percentage inhibition 30.00% 
 
The RFC-based approach was further tested on the Dg.Lib2009 dataset which 
comprises 436 compounds screened against Dengue RdRp. In this retrospective dataset, there 
were 48 confirmed hits. Similar to the ATPSyn.Prestwick Library, the distribution of this 
dataset is also positively skewed (non-Gaussian). First, a Decision Tree was constructed and 
after the first split node (Decision Stump), it selected 24 compounds for reconfirmation 
screening (Figure 2.8). These 24 compounds had a mean percentage inhibition of 64.35% 
while that of the unselected compounds in the other branch was 51.28%. For compounds with 
70% inhibition or higher (see Figure 2.7 and Table 2.5), RFC selected 95 compounds for 
reconfirmation screening. Of these 95 compounds, RFC correctly predicted 18 out of the 27 
confirmed hits in these bins. Decision Stump selected 8 compounds in that percentage 
inhibition range and only 3 were confirmed hits. Confirming the activity of the 27 
compounds would be possible only if the entire 135 compounds in those bins were selected 
for reconfirmation screening. For compounds with less than 70% inhibition, RFC picked 15 
out of 21 compounds. This is particularly interesting since the µ+3σ method is unlikely to 
select compounds from these bins (with low percentage inhibition) for reconfirmation. This 
further shows the added value of the RFC approach. Decision Stump correctly predicted only 
1 confirmed hit among the 21 compounds. Furthermore, the µ+3σ method is not applicable to 
this dataset since the µ+3σ value is 105.04% (Table 2.4) when the compound with the highest 





method, no compound should be sent for reconfirmation screening. Therefore, for the 
Dg.Lib2009 dataset, the RFC method has outperformed the de facto µ+3σ method. However, 
for a primary screen hit list with less than 1000 compounds, it is expected that no compounds 
will be sent for reconfirmation screening. Hence it is possible that such a comparison is not 
an adequately fair one. 
 
With reference to Table 2.5, the “Confirmed Hits” sub-column under the “Untreated” 
column may be regarded as the maximum (ideal) number of confirmed hits that RFC and 
Decision Stump can attain. As such, RFC and Decision Stump cannot possibly predict more 
Confirmed Hits than those numbers given in that sub-column. In the ideal hypothetical 
scenario, RFC should achieve 48 Confirmed Hits out of 299 putative actives (or around 16%) 
and Decision Stump should achieve 24 Confirmed Hits out of 24 putative actives (100%). 
However, RFC only achieved 11% (33/299) instead of the maximum possible 16%. Decision 
Stump achieved 16.7% (4/24) instead of the maximum possible 100%. The most important 
assessment criterion for the purpose of this work is the method’s ability to pick out active 
compounds rather than its ability to pick out inactive compounds. Therefore, the performance 
of Decision Stump is relatively more disappointing since it was expected that all 24 putative 
actives should be Confirmed Hits. The respective number of Confirmed Hits for RFC and 
Decision Stump should be as close to the “Confirmed Hits” sub-column under the “Untreated” 
column as possible.  
 
Another possible way to assess the relative performance of RFC and Decision Stump 





Confirmed Hits in this dataset). In this way, RFC achieved 68.8% and Decision Stump 
achieved 8.3%. Once again, RFC performed relatively better than Decision Stump.  
 
However, it can be argued that the RFC did not perform better than random selection 
for this dataset since the number of confirmed hits that it identified is approximately 11% out 
of the 299 putative actives. Incidentally, the total number of confirmed hits in this dataset is 
also approximately 11% of the total number of compounds. In fact, following this line of 
argument, Decision Stump seems to have performed better at 16.7%.  
 
It is also important to look beyond the total number of confirmed hits that have been 
selected by the various methods; Figure 2.9 shows the IC50 distribution of the Confirmed Hits 
from Bins 100, 90 and 80. The RFC correctly predicted all 3 confirmed hits in the 100% 
inhibition bin (Figure 2.9a) while Decision Stump correctly predicted only 1 compound (IC50: 
9.99µM). In the 90% inhibition bin (Figure 2.9b), there were 13 confirmed hits. The RFC 
correctly predicted 6 of them as actives but Decision Stump correctly predicted only 2 
compounds as actives. In the 80% inhibition bin, there were 11 confirmed hits (Figure 2.9c) 
of which 9 were predicted as actives by RFC whereas Decision Stump incorrectly predicted 







Figure 2.8 Decision tree generated using primary screen activity data of the Dg.Lib2009 Dataset. The numbers 
at the leaf nodes are the mean percentage inhibition values for the respective branches 
 
 














≥ 0 to <10 0 0 0 0 0 0 
≥ 10 to <20 0 0 0 0 0 0 
≥ 20 to <30 1 0 1 0 5 0 
≥ 30 to <40 144 1 101 1 2 0 
≥ 40 to <50 97 3 61 1 2 0 
≥ 50 to <60 59 8 41 5 5 1 
≥ 60 to <70 53 9 37 8 2 0 
≥ 70 to <80 40 11 33 9 5 0 
≥ 80 to <90 32 13 20 6 3 2 
≥ 90 to <100 9 3 5 3 0 1 
≥ 100 to <110 1 0 0 0 0 0 
≥ 110 0 0 0 0 0 0 




























































































































Figure 2.9 Frequency histogram showing the number of compounds selected using various methods from a) the 






2.3.2 PERFORMANCE OF RANDOM FOREST CLUSTERING USING HOPKINS-
BASED SELECTED DESCRIPTORS VERSUS 14 DESCRIPTORS 
 
 
Figure 2.10 Frequency histogram showing the number of compounds selected by RFC using two different sets 
of descriptors. 
 
The results in the previous section were based on the 14 hand-picked descriptors. In 
this section, the results obtained by using the method based on Hopkins Statistic will be 
compared to those obtained using the 14 hand-picked descriptors. For the ATPSyn.Prestwick 
dataset, the results from the Hopkins-based descriptors (Figure 2.10) were very similar to 
those obtained using the 14 hand-picked descriptors. The Hopkins-based descriptor selection 
method picked the 25 descriptors listed in Table 2.6. Out of these, only 2 descriptors (E and 
E_rvdw) were among the 14 handpicked descriptors, i.e. there were no other overlaps. 


























































































performance was not affected. This may indicate that those 14 handpicked descriptors may be 
redundant. However, the reasons behind why the RFC performance was not affected remains 
to be investigated. 
 
Table 2.6 The 25 descriptors selected by the Hopkins-based method for use in the analysis. 
Descriptors 















Using the BCG.Prestwick data, the results from the Hopkins-based descriptors (Figure 
2.11) were very similar to those obtained using the 14 hand-picked descriptors. The Hopkins-
based descriptor selection method picked the 20 descriptors listed in Table 2.7. Of these, no 
overlap with the 14 handpicked descriptors was observed. It can be argued that the presence 





because these descriptors measure the internal energy of the conformation of the molecules. 
They are usually not comparable between different molecules.  
 


















Figure 2.11 Frequency histogram showing the number of compounds selected by RFC using two different sets 
of descriptors. 
 
 Using the Dg.Lib2010 dataset (Figure 2.12), the results from the Hopkins-based 
descriptors (Figure 2.13) were again similar to those obtained using the 14 hand-picked 
descriptors. The Hopkins-based descriptor selection method picked the 28 descriptors listed 
in Table 2.8, of which only 2 descriptors (E and E_rvdw) were among the 14 handpicked 






























































































Figure 2.12 Frequency histogram showing the number of compounds selected by RFC using two different sets 
of descriptors. 
 
Figure 2.13 Frequency histogram showing the number of compounds selected by RFC using two different sets 
of descriptors. 
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The methodology used in this work, the application of the Random Forest Clustering 
method and the two descriptor selection techniques proved modestly successful in accurately 
identifying most of the actives from HTS datasets. The datasets were results from screening 
campaigns on Cell based and Enzymatic screens. There is, however, some indication that 
there may some dataset-dependence with regards to the performance of RFC. The 
distributions were positively skewed, as is usual for high throughput screens where the 
application of the +3, as is currently used, is not truly applicable. The method has been 
shown to be modestly better than the +3 cut-off method in retrieving actives, in addition to 
selecting true positives that could have been easily missed if the latter method had been 
applied. This is vitally important in a drug-discovery project where the retrieval of a reliable 
starting scaffold from a HTS screen is of paramount importance to the success and the 
economics of the discovery of novel therapeutics within the current pharmaceutical paradigm.   
 
From the first descriptor selection method, the ‘hand-picked 14 descriptors’ were 





across the datasets used in retrieving confirmed actives from the other datasets. These 
descriptors (Table 2.2) include the molecular properties proposed in Lipinski’s Rules 189, 
energetics of the molecule and other structural features such as van der Waals surface area, 
the number of rings and presence of reactives groups. These molecular features are important 
in the screening process used to generate the result datasets. logP(o/w) is related to the 
solubility of the compounds in the screened libraries, which is a measure of the quantity of 
compound available to the disease vector (bacteria, virus) in the screening system. 
Intermolecular interactions between the molecule and the disease target are enhanced by the 
presence of Hydrogen bond acceptors and donors. Furthermore, molecular flexibility and the 
presence of rotatable bonds allow the structure to adapt to the shape of the binding pocket 
facilitating more interactions between the hit compound and the protein in the disease vector 
that is being targeted in the screening process. These 14 descriptors may be regarded as a 
generic descriptor set that is suitable for hit retrieval from HTS datasets. 
 
Nevertheless, it is desirable to have an objective method for descriptor selection. The 
Hopkins method was used and has been shown to be suitable in selecting true positives from 
all of the screening datasets used in this study. The Hopkins descriptor selection method 
performs as well as the 14 handpicked descriptors and is able to eliminate 70 to 90% of the 
total number of descriptors used as input, an important aspect in reducing the dimensionality 
of the problem. The descriptors used in the RFC method as applied here, modestly 
outperformed the µ+3σ method that was used as the benchmark.  
 
Random Forest Clustering handles skewed datasets modestly well in addition to 





the effectiveness of the method on large datasets (with more than 2500 compounds) should be 
further explored in the future. One example of using memory intensive computers for large 
datasets is Apache Hadoop. It is an open-source software framework that supports data-
intensive distributed applications.  
 
After the hit compounds have been re-confirmed, there is often a need to understand 
the reasons behind their biological activities and level of potency. In the next chapter, a 
technique to decipher which substructures may account for the potency for a set of 
















CHAPTER 3 EXTRACTION AND VALIDATION OF 





Kinases are popular therapeutic targets, particularly for cancer-related indications. 
190-
192
 Eukaryotic kinases are divided into eight groups based on the sequence similarity of their 
catalytic domains the presence of accessory domains, and their modes of regulation. 
193
 These 
groups are TK (Tyrosine Kinase), AGC (named after the Protein Kinase A, G, and C 
families), CAMK (Ca2+/calmodulin-dependent kinase), CMGC (named after a set of families 
CDK, MAPK, GSK3 and CLK, CK1 (Cell Kinase 1), STE (homologs of the yeast STE7, 
STE11 and STE20 genes), TKL (Tyrosine Kinase-Like) and a miscellaneous group termed 
“Others”.  
 
Achieving selectivity for kinase inhibitors remains a daunting challenge. 
194-203
 Given 
the significant amount of activity data accumulated in the published literature, it is of interest 
to determine if the data could be mined to yield signature profiles of substructures that were 
highly correlated to good potency among known kinase inhibitors. Such substructure profiles 
would correspond to pre-defined structural motifs that are specific to the respective kinase 
targets. Ligands that bind to a given kinase should share common chemical features which 
are absent in random compounds that do not bind to the specified kinase. The substructure 
profiles are anticipated to be useful in two ways: 1) They can be used to prioritize compounds 





pharmacophore-like features to be incorporated or prospectively avoided when designing 
novel inhibitors that interact selectively with a particular kinase target or family. 
 
Fragment co-occurrence analysis is primarily concerned with comparing fragment sets 
in a pair-wise manner. The FragFCA approach identifies fragments and fragment 
combinations that are specific for compounds exhibiting different activity profiles or that are 
unique to highly potent molecules.
204, 205
 Lameijer and co-workers split the NCI databases 
into more 60,000 fragments and identified “chemical clichés”, i.e. the most frequently 
occurring fragments as well as the frequently co-occurring pairs of fragments. 
206
 A group 
from Eli Lilly built naïve Bayes models for predicting potency in individual kinases by 




In this work, we apply the concept of Correlation Rules to uncover substructures that 
are represented with greater frequency in known potent inhibitors vis-à-vis inactive 
compounds and vice versa. 
 




 was primarily used in market basket analysis. Market basket 
analysis analyzes the purchasing patterns of customers by finding associations between the 
items that customers placed into their shopping carts. Typically, such associations are derived 
by mining past transaction records. It is of interest to the retailer to discover that customers 





purchased with particular brands of jam. The retailers can then use such associations to 
optimize profits by coming up with targeted marketing campaigns or promotions that make 
use of such information. 
Each product in a customer’s shopping cart is represented as a Boolean variable, 
indicating whether an item is present or absent. Each transaction is therefore a vector of 
Boolean characters. The analysis of such vectors across all transactions would reflect which 
products are frequently purchased together (across all customers). If two or more products are 
frequently purchased together, they are said to be associated. The rules that describe such 
associations are therefore termed Association Rules. 
 
Given a non-empty item-set I, an Association Rule is a statement of the form A → B, 
where A, B ⊂ I such that A ≠ ∅, B ≠ ∅, and A ∩ B = ∅. The item-set I consists of set A, 
called the antecedent of the Association Rule, and set B which is the consequent of the rule. 
Association rules provide information of co-occurrence patterns in the form of “if-then” 
statements, the antecedent being the “if” part and the consequent being the “then” part. In the 
context of the investigations discussed in this paper, set A consists of a binary indication of 
each compound’s potency while Set B indicates the presence or absence of a particular 
substructure motif in the compound. Association Rules are mined over a set of compounds 
denoted T.  
Support s(A→B) = P(A,B)  (1) 
Support s(A) = P(A)   (2) 






An Association Rule has two properties that indicate its degree of uncertainty. The 
Support s(A→B) (Equation 1) of an Association Rule is the percentage of compounds in the 
database that contains the presence of A and of B in I. P(A,B) is the probability that A and B 
are simultaneously present. Hence the Support is essentially the probability that a randomly 
selected compound from the database will contain all items in the antecedent and the 
consequent, i.e. the compound will be potent as well as contain a particular substructure motif. 
The Confidence c(A→B) (Equation 3) of an Association Rule is the ratio of the Support 
s(A→B) to the number of compounds that are potent (the antecedent), regardless of the 
presence of any particular substructure. Therefore, the Confidence is P(B|A) which is the 
conditional probability that a randomly selected compound will contain a particular 
substructure (the consequent) given that the compound is potent (the antecedent). Typically, 
only Rules that have Confidence and Support values above certain user-defined thresholds 
would be extracted.  
 
3.3 SHORTCOMINGS OF THE SUPPORT-CONFIDENCE FRAMEWORK 
The Support-Confidence framework is not without its shortcomings. Notably, it is 
likely to generate too many rules. In addition, a high Confidence value can be misleading. If 
the antecedent or consequent has a high Support value, the Confidence value will be high 
even if they are independent of each other, i.e. not correlated. Association Rules also fail to 
capture many dependencies among items. Moreover, the framework does not allow for the 
elucidation of negative implications in which the presence of the antecedent is associated 
with the absence of the consequent. In this regard, the Lift Ratio (Equation 4) provides a 





The shortcomings of the Support-Confidence framework are illustrated in the example 
given in Table 3.1. In this Table, the rows correspond to compounds that are potent or not 
potent respectively, and the columns correspond to the presence or absence of a particular 
Substructure X. The numbers in each cell represent the percentage of the total number of 
compounds in the dataset. By applying the Support-Confidence framework based on the 
Association Rule [Potent → Substructure X present], the Support for this rule s(Potent→ 
Substructure X Present) is 20%. The Confidence c(Potent→ Substructure X Present) is 20÷25 
= 0.8 or 80%. Based on this framework, it is tempting to conclude that the rule [Potent → 
Substructure X present] is valid. However, 90% (20% + 70%) of the compounds in the 
dataset actually contain Substructure X, regardless of potency. Based on the distribution of 
Substructure X among the compounds in the dataset, a non-potent compound is 3.5 times 
(70÷20) more likely to contain Substructure X. Hence, contrary to the [Potent → 
Substructure X present] rule, there is a negative correlation between potency and the presence 
of Substructure X.  
Table 3.1 A contingency table showing an example of the frequency count of each property as a percentage of 
the total number of compounds in the dataset. 
 Substructure X present Substructure X absent 
Potent 20% 5% 
Not Potent 70% 5% 
 
The Lift Ratio is a means of quantifying this correlation (Equation 4). For a pair of 
attributes [Potent, Substructure X present], the Lift Ratio is calculated as the Support value 
for that pair, divided by the product of the individual Support values for [Potent] and 
[Substructure X present] (Equation 2).  












The Lift Ratio gives a measure of the extent to which the equation P(Potent, 
Substructure X present) = P(Potent)×P(Substructure X present) is true. In this example, the 
Lift Ratio is 20 ÷ (25×90) ≈ 0.009. The fact that this quantity is significantly less than 1 
indicates a negative correlation between potency and the presence of Substructure X. Hence 
correlation is the more appropriate measure since the Support-Confidence framework has 
failed to detect such relationships. If the Lift Ratio equals 1, then potency and the presence of 
Substructure X are independent. When the Lift Ratio exceeds 1, then the larger the value, the 
more likely it is that potency and the presence of Substructure X in a compound is not a 
chance occurrence but imply a positive relationship between them (if compound is potent, 
Substructure X is also frequently present). As such, a Correlation Rule 
209, 210
 says that the 
items in an item-set are dependent. Hence the application of Correlation Rule allows us to 
investigate the presence of such relationships, instead of just identifying the positive 
relationships which are implicated by the Association Rules. Correlation Rules do not rely on 
the Support-Confidence framework to establish their validity. Together with the value of Lift 
Ratio, the statistical significance of the independence of A and B was checked by conducting 
the chi-squared test for each [Potent, Substructure X present] pair. 
 
In order to illustrate the superiority of Correlation Rules, we applied the Correlation 
Rules and Association Rules to the same datasets. And as described later, we found 
Association Rules to perform poorly. One reason for the poor outcome may be traced to the 
composition of the datasets where active compounds comprise only between 4.5% and 18.9%. 
At these levels, the Support s[Potent → Substructure X present] is also low. Hence using the 
Minimum Support of 60% and the Confidence set at 60%, the Association Rules approach 





This is one of the shortcomings of the Association Rules that is not encountered with 
Correlation Rules 
209, 210
 which does not require the setting of pre-determined thresholds. 
 
3.4 MATERIALS AND METHODS 
Datasets 
The structural and potency data contained in the curated Kinase SARfari  dataset of the 
ChEMBL database 
212, 213
 were used. Two kinases were selected from three of the kinase 
groups. They were CDK2 (cyclin-dependent kinase 2) 
214
 and p38 alpha 
215
 from the CMGC 
group, EGFR (epidermal growth factor receptor) 
216
 and SRC 
217
 from the TK group, AKT1 
218
 and PKCβ (Protein Kinase C beta) 219 from the AGC group. 
 
Data pre-processing 
Only compounds with available IC50 and Ki values were retained. For the compounds 
with activity data against the six selected kinases, the IC50 and Ki values of the compounds 
were discretized into binary labels of 1 (active) and 0 (inactive). A compound was labelled 1 
if its IC50 value is less than or equals to 5µM and labelled 0 if that is more than or equals to 
100µM. Compounds with IC50 values against the six selected kinases that do not meet these 
labelling criteria were discarded. Similarly, a compound was labelled 1 if its Ki value is ≤ 2.5 
µM and labelled 0 if it is  50 µM. Compounds with IC50 value between 5µM and 100µM 
and Ki value between 2.5 µM and 50 µM were discarded to ensure that only the substructures 






The 100M IC50 threshold was chosen for the following reasons:  
 It is generally accepted that compounds with such IC50 values or higher are considered 
inactive.  
 There is a 20-fold difference over the IC50 threshold for active compounds. This 
difference is necessary to ensure that the substructures to be elucidated are truly 
representative of the active and inactive compounds respectively.  
 
The 5M IC50 threshold was chosen for the following reasons:  
 Although there is a lack of active compounds in the Kinase SARfari database, there is still 
a need for certain stringency in the definition of potency. Raising this threshold will 
reduce the fold difference with the inactive compounds. However, if the IC50 threshold is 
made more stringent by lowering it any further, the result will be an insufficient number 
of active compounds for data analysis. 
 
The thresholds for Ki were converted from the respective IC50 thresholds by assuming Ki 





Augmentation with decoy compounds 
Due to the imbalance in numbers of potent compounds versus inactive compounds, 





selected randomly from the ChEMBL database. 
212, 213
 Since these compounds were treated as 
putative inactives, they were labelled 0. The overcompensation for the lack of inactive 
compounds was necessary so as to ensure that there is sufficient structural diversity in the 
putative inactive set. This was demonstrated in the mean Tanimoto coefficient scores (Figure 
3.2). It was observed that the inter-quartile range of the mean Tanimoto coefficient scores of 
the datasets were between 0.54 and 0.59. In this report, the decoy compounds were not 
filtered to remove compounds that have similar physicochemical properties or structural 
/topological compositions. Although there are methods available to achieve these 
objectives,
168, 221
 they were not considered here because this would introduce significant bias 
into the decoy compounds by accentuating the difference between the decoys and the 
compounds being investigated in an artificial manner. This is especially so since the method 
used in the study is primarily based on the structural composition of the compounds. Hence 
the filtering process was not implemented in this investigation. This level of structural and 
physicochemical diversity is probably a realistic representation of the diversity of compounds 
frequently encountered in high-throughput screening compound collections. Adding just 
enough putative actives to balance the dataset will not introduce sufficient structural diversity 
for the substructure profile elucidation using Correlation Rules. Molecules that are identical 
to active compounds were, however, removed from the decoy compounds and replaced with 
non-identical random compounds. The composition of the datasets is given in Table 3.2. The 
molecules that were identical to those compounds which were discarded due to their activities 
lying between the two threshold values were also excluded from the decoy compounds. 
Table 3.2 Composition of kinase datasets used in the study. 
Target Number of compounds 
Group Kinase Active Inactive Augmented Total 





SRC 1566 162 8000 9728 
AGC AKT1 623 133 8000 8756 
PKCβ 396 363 8000 8759 
CMGC CDK2 1607 163 8000 9770 
p38α 1941 315 8000 10256 
 
In order to investigate the effects of substructures, molecular fingerprints were 
generated using PaDEL-Descriptor 
222
, a software that calculates molecular descriptors and 
fingerprints. A total of 166 Molecular ACCess System (MACCS) fingerprint keys 
102
 and 881 
PubChem 
223, 224
 fingerprint keys  in binary format (indicating presence or absence) were 
computed for each compound. In addition, for performance comparison purposes, 4860 
fingerprints as investigated by Klekota and Roth 
226
 were computed in binary format for each 
compound in the AKT1 and p38α datasets. 
 
Fingerprint keys selection and validation 
A five-fold validation methodology was applied. Each dataset was divided equally and 
randomly into 6 subsets: Validation Sets 1 – 5 and a Test Set. At any one time only four of 
the five Validation Sets were used to derive the Correlation Rules. The Test Set was not used 
in any of the validation processes. Each of the 1047 fingerprint keys was then used to create a 
contingency table for the pair-wise comparison of substructure and activity. A total of 1047 
contingency tables were generated for each kinase. The Lift Ratio was computed for each 






Table 3.3 An example of a contingency table for a pair-wise comparison between activity and a particular 
fingerprint key 
 Fingerprint key present Fingerprint key absent 
Active F1 F2 
Inactive F3 F4 
 
The number or frequency of compounds (F1, F2, F3 and F4) that corresponds to each of 
the four cases is listed in Table 3.3. In addition, a series of Contrast scores were calculated. 
These scores are intended to assess the influence of the presence or absence of each 
Fingerprint key on the potent and non-potent compounds respectively. 
Contrast 1 = F1/ (F1+F2)  (5) 
Contrast 2 = F2/ (F1+F2)  (6) 
Contrast 3 = F3/ (F3 + F4)  (7) 
Contrast 4 = F4/ (F3 + F4)  (8) 
Lift Distance = | 1- Lift Ratio |  (9) 
 
Particular attention is paid to Contrast 1 (Equation 5) and Contrast 4 (Equation 8). 
Contrast 1 gives the proportion of actives that have a particular fingerprint key while Contrast 
4 reports on the proportion of inactives that do not have the same fingerprint key. If both 
Contrast 1 and Contrast 4 have values that are equal or greater than 0.8, then the potency-
fingerprint key pair will have its Contrast Quality label set to “Excellent” (Table 3.4). If the 
scores are between 0.79 and 0.7, then the Contrast Quality label is set to “Good”. If their 
scores are between 0.69 and 0.6, it is deemed “Moderate” and if less than 0.6, it is considered 





generated from Contrast 2 (Equation 6) and Contrast 3 (Equation 7). A Lift Distance score 
(Equation 9, the absolute distance of the Lift Ratio from the value of 1) is then computed for 
each cell in the contingency table. The Lift Distance scores are summated to obtain the Total 
Lift Distance score, which is used to sort the Fingerprint Keys. A high Total Lift Distance 
score indicates that a particular Fingerprint Key is highly correlated (positively or negatively) 
to potency. In addition, a Chi-square test was conducted for each potency-fingerprint key pair 
to confirm that the pair is not independent at 95% confidence. If the Fingerprint Key fails the 
Chi-square test, it is discarded. 
 
Table 3.4 Criteria for Contrast Quality labels 
 Contrast Quality label 
 Excellent Good Moderate Poor 
Contrast 1 
Both ≥ 0.8 0.79 < Both ≤ 0.7 0.69 < Both ≤ 0.6 Both < 0.6 
Contrast 4 
Contrast 2 




In the final step, fingerprint keys with Contrast Qualities computed to be “Excellent”, 
“Good” or “Moderate” are prioritized in descending order of their Total Lift Distance scores, 
i.e. highest Total Lift Distance scores on top. If there are more than 10 such fingerprint keys, 
then only the top 10 keys with the highest Total Lift Distance will be used for screening the 
Test Set and the five Validation Sets. If there are less than 10 such fingerprint keys, then all 






Scoring the compounds 
The selected Fingerprint Keys are used to score the compounds in the respective datasets. For 
the screening of the Test Set and the five Validation Sets of compounds, the binary codes 
(indicating presence or absence) of each of the selected Fingerprint Keys were substituted by 
the (Lift Distance)present and (Lift Distance)present respectively. The (Lift Distance)present is the 
summation of the Lift Distance values for all compounds containing a particular Fingerprint 
key. The (Lift Distance)present therefore serves as a penalty for compounds that do not 
contain the Fingerprint Key. Finally, for each compound in the Test Set and the remaining 
Validation Set, the (Lift Distance)present and (Lift Distance)present are summed to give the 
Decision score. The compounds are then sorted in descending order of their Decision scores. 
Thereafter, the compounds are segregated into 10 deciles, each containing a similar number 
of compounds. Decile 1 will have compounds with the highest Decision score (high 
probability that these compounds will be potent) and Decile 10 comprise compounds with the 
lowest Decision score (low probability that these compounds will be potent).  
 
Performance evaluation 
Predictive accuracy measures are often used to evaluate the performance of classifiers. 
227
 However, for methods based on scoring, this is inadequate for the following reasons: First, 
predictive accuracy measures typically compute the percentage of compounds that are 
classified correctly (or erroneously) by the classifier. This is inappropriate for the evaluation 
of the Decision score since the scoring procedure does not have the concept of correct or 
incorrect classification. Each compound is merely assigned a numerical value that indicates 
the likelihood of it belonging to the active class. Second, predictive accuracy generally does 





and therefore are unable to evaluate the Decision score effectively. In view of these 
limitations, an Enrichment Factor was used here to evaluate performance. The Enrichment 
Factor gives the cumulative percentage of potent compounds from Decile 1 to the next decile 
compared to the random distribution of the potent compounds under similar conditions when 
the Correlation Rules are not applied. If the cumulative percentage of active compounds in 
the top three deciles exceeds 70%, the Decision score is deemed to be capable of selecting 
and prioritizing active compounds embedded within a large dataset.  
The performance of the Correlation Rules approach was also compared to the 
classical similarity search using the same 1047 fingerprint keys. The size and graphical 
atomic extent of the fingerprints used in this study can be viewed as having less chemical 
relevance and are more promiscuous in picking up compounds of interest. This concern was 
addressed by analyzing two of the data sets using a different set of 4860 fingerprint keys 228 
containing more chemically-meaningful fragment sizes as a comparison. 
 
Diversity of the datasets 
The similarity between the active compounds in each dataset and the compounds in the 
reference set (inactive and augmented sets of compounds) were investigated by computing 
the mean Tanimoto coefficient 
229
 scores. These scores were obtained by first calculating the 
Tanimoto coefficient of each active compound against each reference set compound in a pair-
wise manner based on the same 1047 fingerprint keys used for elucidating the substructure 
profiles. Thereafter, the averages of these Tanimoto coefficient scores were calculated. These 






3.5 RESULTS AND DISCUSSION 
Fingerprint keys selection 
For every dataset, each of the Fingerprint keys was scored in a pair-wise manner 
(Potency-Fingerprint Key) in order to ascertain its level of correlation with potency. Tables 
3.5 to 3.10 record the graphical depictions of the 10 top-scoring fingerprint keys from the 
corresponding Validation Set 1 and Test Set of each dataset. Attention should be drawn to 
PKCβ Validation Sets 4 and 5 (Table S1.1, Appendices), they contain only 9 selected 
Fingerprint Keys. This is because only 9 Fingerprint Keys received the Moderate label or 







Table 3.5 The top 10 fingerprint keys of the EGFR validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 

























































Table 3.6 The top 10 fingerprint keys of the SRC validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 






















atom with a charge of not +0  
 
MACCSFP49 



































Table 3.7 The top 10 fingerprint keys of the AKT1 validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 
 AKT1 Validation Set 1 AKT1 Test Set 
1 
atom with a charge of not +0  
 
MACCSFP49 




 4 aromatic rings 
 
PubchemFP261 




 2 hetero-aromatic rings 
 
PubchemFP258 





























 4 N 
 
PubchemFP16 














Table 3.8 The top 10 fingerprint keys of the PKCβ validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 
 PKCβ Validation Set 1 PKCβ Test Set 





 2 any ring size 5 
 
PubchemFP150 

















































Table 3.9 The top 10 fingerprint keys of the CDK2 validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 






























































Table 3.10 The top 10 fingerprint keys of the p38α validation and test sets selected by the scoring scheme. 
Dashed lines and circles denote aromatic bonds and atoms respectively. Continuous lines and circles denote 
aliphatic bonds and atoms respectively. Curly lines denote any bond type and the question mark denote any 
atom. 


























































The prediction results of the six datasets were evaluated using five-fold cross 
validation and external validation. The results are given in Figure 3.1. 
 
For the EGFR dataset, slightly more than half of the potent compounds in Validation 
Sets 1-5 (average of 51.6%) were found within the 1
st
 Decile (Figure 3.1a). Compared to the 
random selection of actives, the Correlation Rules approach outperforms by approximately 5 
times (Figure 3.1a). By the 3
rd
 Decile (i.e. top 30% of each Validation Set), an average of 
84.9% of the potent compounds had been picked up and by the 7
th
 Decile, all the potent 
compounds in each Validation Set were successfully identified. The external validation of the 
EGFR Test Set produced comparable results. Equally good results were obtained with the 
SRC dataset (Figure 3.1b) where nearly 87% of the potent compounds in the Validation Sets 
were identified by the 3
rd
 Decile. The external validation of the SRC Test Set produced 
comparable results. In the same way, 63.6% of actives (average of 5 Validation Sets) in the 
PKCβ dataset (Figure 3.1d) were identified in the 1
st
 Decile and 89.1% in the 3
rd
 Decile. The 
external validation of the PKCβ Test Set produced comparable results. Of the 5 PKCβ 
Validation Sets, the best outcome was obtained with Validation Set 4 where 84.8% of actives 
were picked up in the 1
st
 Decile.  
Even more impressive results were obtained with the AKT1 dataset (Figure 3.1c). 
Here, an average of 87% of actives were captured in the 1
st
 Decile and by the 3
rd
 Decile, 96.5% 
of the actives were identified. On inspection, it was found that the AKT1 Validation Set 1 
outperformed the other Validation /Test Sets, with 96.1% of actives captured in the 1
st
 Decile 
and all actives (100%) by the 2
nd






In contrast to the other kinase datasets, the actives in the CDK2 and p38α datasets 
were less readily identified by the Correlation Rules. Only 34.8 % of actives were identified 
in the 1
st
 Decile for the CDK2 Validation Sets although the situation improved somewhat by 
the 3
rd
 Decile with 78.3% actives successfully identified. In the case of the p38α dataset, an 
average of 56.6% of the actives was identified in the 3
rd
 Decile which compared poorly with 
the other kinase Datasets.  
 
It is interesting to note that these two underperforming datasets comprise compounds 
that target kinases from the same (CMGC) group. This may suggest that the mechanism of 
action of these compounds may be less dependent on their chemical structures compared to 
compounds in the other datasets.  Other factors may be exerting a relatively larger influence 
on the biological activities of the compounds in these two datasets. It is possible that these 
compounds are more dependent on the conformation of the binding site on the respective 
kinases. The Correlation Rules method was not designed to account for such conformation-
specific binders. While it is possible that the conformation specificity of some of the 
compounds account for their biological activities, the Correlation Rules method is inherently 
a two-dimensional approach. Therefore, one of its limitations is its inability to differentiate 





























































































































































































































































Figure 3.1 Enrichment curve of the five-fold cross validation results using the respective datasets. The plots 
show the cumulative percentage of the active compounds at each decile. 
 
 
We recognize several limitations to our method. One shortcoming is that the 
comparisons were conducted in a pair-wise manner, i.e. each Fingerprint Key was 
independently compared to potency. This approach may increase the likelihood of selecting 





approach is to take into account multiple Fingerprint Keys at the same time but this will lead 
to a network of significantly more complex many-to-many relationships between the 1047 
Fingerprint Keys. Hence the current approach remains a more viable option. The other 
limitation is that the substructures defined by the Fingerprint Keys may be too small in size to 
be useful to medicinal chemists for lead optimization. However, if the selected substructures 
are treated as a signature profile for a specific protein target, it can still be useful for 
enriching compound libraries or for prioritizing compounds. Most of the top 10 selected 
Fingerprint Keys remained stable within each dataset. There was also no significant overlap 
between the selected Fingerprint Keys across datasets. This indicates that our approach is 
able to pick out unique substructure profiles even among members of the same kinase group. 
The ability to distinguish between compounds designed for intra-group kinases would be 
highly useful in highlighting compounds that are more selective. Alternative fragmentation 
methods may also be employed to define the substructures. In particular, methods that give 
rise to entities that fall within the size range of fragments would be of particular interest to 
medicinal chemists. Another approach is to apply our method to extract substructures from 
fragment-based screening data instead of data from complete compounds as we have 
investigated in this paper. Clearly, the effect of the number of random compounds to be 
augmented to the datasets requires further investigation. 
 
Taken together, our investigations have shown that Correlation Rules can be applied 






Diversity of the datasets 
The box-and-whisker plots for all the six datasets are shown in Figure 3.2. It is 
observed that the inter-quartile ranges of the mean Tanimoto coefficient scores of the datasets 
fall between 0.54 and 0.59. The narrow inter-quartile range indicates that the active 
compounds are structurally more similar among themselves as compared to compounds in the 
reference set (inactive and augmented compounds). Moreover, since the comparison in the 
box-and-whisker plots is made against the reference set, the corollary is that the active and 
reference compounds are to a certain extent, structurally dissimilar. The structural similarity 
among the active compounds may reflect the fact that compounds intended as kinase 
inhibitors tend to be rationally designed and thus, likely to contain similar motifs or scaffolds. 
In addition, the curated data found in the ChEMBL Kinase SARfari database contain mostly 
compounds from analogue series extracted from medicinal chemistry literature rather than 
compounds with diverse scaffolds. In contrast, the 8000 augmentation compounds were 
randomly selected without prior filtering by physico-chemical or structural/topological 
criteria. Consequently, their mean Tanimoto coefficient scores would be relatively higher, as 
observed in Figure 3.2. A more elaborate filtering scheme such as those adopted by others 
168, 
221
 may give rise to lower mean Tanimoto coefficient scores but this would be achieved at the 
expense of artificially enhancing structural diversity to some degree. We have shown here 
that even without artificially enhancing structural diversity, promising enrichment results 
could be achieved by applying Correlation Rules for the extraction of substructure profiles.  
 
It can be seen from Table 3.1 that ratios of active compounds to total number of 
inactive and augmented compounds vary among the six datasets. Notably, ratios for the AGC 





the CMGC kinases (CDK2 1:5; p38α 1:4) and TK kinases (EGFR 1:4; SRC 1:5). 
Coincidentally, the AGC kinases showed the best enrichment profiles (Figure 3.1) which 
suggests that increasing the number of augmentation compounds to the extent found in the 















































Figure 3.2 Box-and-whisker plots of the mean Tanimoto coefficient scores of the active compounds in each 
dataset when compared against the inactive compounds and augmented compounds. Ends of the whiskers 
represent the minimum and maximum mean Tanimoto coefficient scores of all the compounds in each dataset. 
 
Comparison with classical similarity search 
The consequences of using a classical similarity search method were investigated as a 
comparison. The questions we have tried to answer are: (1) if a known active compound is 
used as a similarity matching template to select compounds from a retrospective database, 
how many of those compounds picked up based on high structural similarity would be a 
known active compound and (2) the minimum level of structural similarity required in order 





between each active compound and all the other active compounds in each dataset. The 
Tanimoto coefficient scores were generated based on similarity matching using the same 166 
MACCS and 881 PubChem fingerprint keys. In this case, however, no selection or filtering 
was done to the fingerprints, i.e. all 1047 fingerprint keys were used for similarity matching.  
 
In conducting a similarity search, it is necessary to use a cut-off value above which, 
molecules are considered to be similar. This value is subjective and the retrieval of the 
number of similar compounds (or active compounds in this application) is dependent on this 
value. The results (Figure 3.3) show that using any one of the active compounds as the 
template for similarity matching at Tanimoto coefficient score > 0.7 is unlikely to pick up 
more than 44% of the active compounds in each dataset. Moreover, the classical similarity 
search method is unable to assign a priority or importance to each compound that matches the 
template compound at a specific Tanimoto coefficient score. Testing compounds thus mined, 
above a certain similarity score may not necessarily lead to better actives due to the lack of 
priority assignment. The other disadvantage of the classical similarity search method is that it 
is only capable of picking up compounds that are structural analogues of the template 
compound (i.e. highly similar scaffolds) since all 1047 fingerprint keys were used. This may 
not be useful for finding novel scaffolds in the databases made up of diverse scaffolds. 
 
 However, it can be argued that using a cut-off value is inappropriate to evaluate 
similarity search by using the same arguments that was used against using predictive 
accuracy. Further investigations into other methods for a fairer comparison should be carried 
out in future. For example, the compounds could be ranked according to their Tanimoto 
scores and thereafter evaluated using the enrichment factor and possibly the Area under the 































































Figure 3.3 The plots show the cumulative percentage of the active compounds at each bin of the Tanimoto 
coefficient scores. The Tanimoto coefficient scores were calculated based on the comparison of each active 
compound against all other active compounds in each dataset. 
The size and graphical atomic extent of the 1047 fingerprint keys used in this study can 
be viewed as having less chemical relevance and greater promiscuity in picking up 
compounds of interest. To address this concern, we analyzed two of the data sets using a 
different set of 4860 fingerprint keys reported by Klekota and Roth [34] which contain more 
chemically-meaningful fragment sizes. Using the Klekota-Roth fingerprint keys in the 
Correlation Rules approach, it was observed (Figure 3.4) that the enrichment performance for 
the AKT1 dataset was adversely affected. One reason may be that the Klekota-Roth 
fingerprint keys with acceptable Contrast Quality were significantly less than the ones from 
MACCS-PubChem. For AKT1 Validation Sets 4, 5 and Test Set, there were only 4 Klekota-
Roth fingerprint keys with acceptable Contrast Quality. Validation Set 2 had 5 such 
fingerprint keys while Validation Sets 1 and 3 had 8 fingerprint keys. This is despite the fact 





from MACCS-PubChem. The variable number of the Klekota-Roth fingerprint keys across 
the Validation and Test Sets may also indicate instability. 
 
AKT1 dataset








































Figure 3.4 Enrichment curves of the five-fold cross validation results using the AKT1 dataset derived from the 
Klekota-Roth fingerprint keys. The plots show the cumulative percentage of the active compounds at each 
decile. 
 
The results from the p38α dataset were more appalling. All Validation Sets, with the 
exception of Validation Set 3, selected only 1 Klekota-Roth fingerprint key with sufficient 
Contrast Quality. Not surprisingly, this had a detrimental impact on the enrichment 
performance. Since those Validation Sets and Test Set used only 1 Klekota-Roth fingerprint 
key, the assignment of priority was dependent on the presence or absence of fingerprint key 
KR3956 (the C-O aliphatic bond), which made it impossible to plot an enrichment curve. 





active compounds in these Validation Sets and Test Set have been given top priority status 
compared to an average of 54% in the top decile using the MACCS-PubChem fingerprint 
keys. For the p38α Validation Set 3 (Figure 3.5), only 55.9% of the active compounds were 
selected even after 60% of the p38α dataset has been selected. 
The results showed that applying the Correlation Rules to the Klekota-Roth privileged 
substructures did not enrich the selected kinase libraries to the same extent as the 166 
MACCS and 881 PubChem fingerprints. Larger fragments, unlike smaller fragments, are 
possibly less capable of discerning the subtle differences between active and inactive 
compounds. The other observation was that it was harder to match the larger fragments thus 
resulting in a large majority of the Klekota-Roth fingerprint keys being absent in the datasets 
investigated. The small fragments used in the MACCS-PubChem substructure profiles as 
illustrated in Tables 4 – 9 were intended to provide a complete profile, not as individual 









































Figure 3.5 Enrichment curve of the validation results using the p38α dataset Validation Set 3 derived from the 
Klekota-Roth fingerprint keys. The plots show the cumulative percentage of the active compounds at each 
decile. 
 
Several practical applications may be proposed for the Correlation Rules approach 
described here. An obvious application is the follow-up of high-throughput screening (HTS) 
which currently involves substructure and similarity searching using HTS hits or other known 
actives as template compounds. It may be applied to mine the noise in a HTS screen for false 
negatives or as an additional prioritization step in a typical virtual screening workflow. The 
substructure profiles can be used to virtually screen public or corporate compound databases 
during the hit identification phase. Selected compounds will subsequently be docked against 
the therapeutic target of interest. The advantages of the Correlation Rules are that the 
shortlisted compounds are ranked even before they have been assayed or docked, and that the 
ranking is not based on gross structural similarity as would be the case for a classical 





therapeutic target. The approach may also be applied to the derivation of substructure profiles 
that are representative of compounds known to have specific toxicity liabilities. This may 
help to flag potentially worrisome compounds in virtual compound libraries even before they 
have been synthesized. 
 
3.6 CONCLUSION 
In this chapter we have proposed a novel application of Correlation Rules to extract 
substructure profiles that are highly correlated to the potency of compounds known to be 
active against a specific protein target. Comparisons with Association Rules and classical 
similarity search have been performed and the superiority of the Correlation Rules has been 
established for six kinase datasets. Furthermore, a more chemically-meaningful fingerprint 
set was used to compare the success of the method and the dependence of the results on the 
fingerprints used. Taken together, the substructure profiles extracted in this work may be 
used to enrich compound libraries or to prioritize compounds for synthesis or evaluation 
against a specific therapeutic target. 
 
The technique described in this chapter takes a ligand-based approach. This is usually 
applied if the 3D structure of the target protein is not available. In the next chapter, a virtual 






CHAPTER 4 VIRTUAL SCREENING OF COMPOUNDS FOR 





According to the World Health Organization, more than 1 billion people are affected 
by one or more neglected tropical diseases. 
230
 Due to globalized trade and travel, some 
diseases may emerge in developed places or re-emerge where they once were controlled. 
231
 
Although neglected tropical diseases kill an estimated 534000 people worldwide every year, 




Every year, 40 to 100 million people are infected by the dengue virus. In addition, 
more than half of the world’s population live in areas at risk of infection. Transmitted through 
the Aedes aegypti mosquito, it is the most common and widespread arthropod-borne viral 
infection in humans. 
233
 The dengue virus is the causative agent of dengue fever, the 
potentially lethal dengue hemorrhagic fever as well as the dengue shock syndrome. The 
dengue virus belongs to the family Flaviviridae and the genus Flavivirus. Other lethal human 
pathogens which belong to the same family are Yellow Fever, Japanese encephalitis, West 
Nile virus and hepatitis C virus (HCV). There are four serotypes of dengue − DEN-1, DEN-2, 
DEN-3, and DEN-4. While infection with a single serotype of dengue virus is believed to 
provide life-long immunity to that serotype, cross-protection to other serotypes lasts for only 
a few weeks.  
The dengue genome is a single-stranded RNA of plus-sense polarity. The genomic 





The single open reading frame encodes a long polypeptide that is processed by viral and host 
proteases into 10 mature viral proteins 
234
 (Figure 4.1):  
 Three structural proteins [Capsid (C), pre-membrane (prM) and envelope (E)] are 
components of virus particles. 
 Seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) are 
responsible for viral replication, virion assembly and innate immunity antagonism. 
 
Figure 4.1 Translation of the genome by the host cell machinery produces a polypeptide comprising the viral 
structural and non-structural proteins that are required for replication and assembly of new virions. (Figure 
credits: Future Microbiology. 3(2)155.4) 
 
The NS5 protein consists of 2 functional domains: 
 The N-terminal part of NS5 is a methyltransferase that catalyze both guanine N-7 and 
ribose 2'-OH methylations during viral cap formation. 
 The C-terminal part of NS5 has an RNA-dependent RNA polymerase (RdRp) activity. 
 RNA polymerases catalyze the template synthesis of RNA. The template can either be 
DNA or RNA. RdRps use a single-stranded RNA as the template. 
235
 Many RNA viruses 
encode RdRps. Viral RdRps are attractive targets 
236-243





agents since they do not catalyze reactions which are involved in host processes and are 
unique to RNA viruses. In fact, other RdRps of viruses from the same family have been 
targeted for therapeutic purposes with considerable success, as in the case of HCV RdRp. 
30, 
244-318
 Therefore, structural insights into Dengue RdRp should be useful for the development 
of anti-dengue therapeutic agents. Moreover, Dengue RdRp is a novel therapeutic target, the 
other known targets against Dengue include the NS5-associated 2’-O-methyltransferase and 
the multi-functional NS3 protein with protease, helicase and nucleoside-5’-triphosphatase 
(NTPase) activities.  
 
Figure 4.2 Structure of Dengue RdRp depicting the locations of the GTP binding pocket and the allosteric site 
targeted in this work. 
 
The dengue RdRp has been crystallized to 1.85Å resolution (Figure 4.2) PDB ID: 
2J7W. 
319, 320
 There are 3 sub-domains in the structure of dengue RdRp, colloquially 
described as the palm, the fingers and the thumb. Amongst other RdRps, the structurally most 





sequence is conserved in almost all RNA polymerases. The site where the GDD motif exists 
is also known as the GTP binding site. There are two tunnels in the structure of dengue RdRp. 
The first tunnel serves as a ‘template’ tunnel to accommodate a single-stranded RNA 
template strand. This tunnel runs vertically between the fingers and the thumb sub-domains. 
The other tunnel is approximately perpendicular to the first one. This second tunnel allows 
the access of incoming ribonucleoside triphosphates to the active site. The dengue RdRp 
active site is located at the intersection of the two tunnels. The nascent double-stranded RNA 
exits via the front part of the second tunnel. 
Inhibitors of RdRps are largely grouped into nucleoside analogue inhibitors 
245, 254, 255, 
257, 259, 260, 280, 288, 292, 303, 321-323
 and non-nucleoside inhibitors (NNIs) 
246, 247, 249, 250, 275, 279, 281, 294, 
312, 316, 317, 324-328
. Nucleoside analogue inhibitors have several disadvantages. Firstly, there is a 
significant propensity to encounter “activity cliffs” 104 during the interpretation of structure-
activity relationship (SAR) of nucleoside analogues. Such “activity cliffs” are caused by pairs 
of nucleoside analogues that are structurally similar but have large differences in activity. The 
activities of nucleoside analogues are dependent on the combination of host kinases for each 
phosphorylation to form nucleoside triphosphate. Therefore, the kinase-mediated 
phosphorylation efficiency could be dramatically affected by a slight change in either the 
base or ribose moiety, resulting in decreased potency against RdRp. In addition, since 
different cell lines are likely to differ in their expression levels of nucleoside/nucleotide 
kinases, they may show a wide range of antiviral activity 
329
. The concern is that antiviral 
activity may be very low in some cases. Secondly, nucleosides tend to have low or variable 
bioavailability in animal studies because they generally enter cells by passive diffusion due to 
their polar nature. Alternatively, nucleosides may also enter via the nucleoside transporter but 
it depends on the presence and abundance of specific nucleoside transporters in a particular 
cell line and the concentration of the nucleoside analogues. 
330





are prodrugs that must be converted in cells to the triphosphate in order to be active against 
dengue RdRp, the scope for chemical innovation is limited. 
Consequently, in view of these disadvantages, the focus of this work is on the 
discovery of dengue RdRp non-nucleoside inhibitors. There are currently no non-nucleoside 
inhibitors for the GTP binding site hence this site was targeted in the present work. In 
addition, since allosteric sites for the dengue RdRp have not been investigated in detail, the 
allosteric site that was explored in this work might give rise to non-nucleoside inhibitors with 
novel scaffolds. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 ASSEMBLING THE COMPOUND LIBRARIES 
Before any virtual screening was carried out, three compound libraries were assembled 
from a source dataset.  
Table 4.1 Selection criteria for picking compounds from the Novartis company archive. 
Molecular weight  between 300 – 450 
Maximum number of rotatable bonds  6 
Total number of hydrogen bond acceptors and hydrogen bond 
donors  
15 
Calculated LogP  between -2 and 5 
Reactive and toxic compounds 
Do not contain reactive and toxic compounds 
as defined by Oprea’s rules 22 
 
The source dataset composed 213000 compounds from the Novartis company archive 
which satisfied the criteria listed in Table 4.1. The OMEGA module of the OpenEye software 
suite was used to generate a multi-conformation structure database of each compound in 
source dataset. The following settings were used for running OMEGA: 200 conformers per 





were generated. Those conformers will be used to generate the three compound libraries 
mentioned below since the docking software uses a rigid protein-rigid ligand paradigm. 
 
The three compound libraries are: 
 Library A: this library consists of compounds docked into the GTP binding pocket (the 
location of the GDD motif) of the dengue RdRp (PDB: 2J7W).
319, 320
 
 Library B: this library consists of a subset of compounds derived from Library A by 
further filtering using shape and electrostatics-based matching as well as a 
pharmacophore model. 
 Library C: this library consists of compounds docked into the allosteric pocket of an in-
house allosteric ligand-bound crystal structure of the dengue RdRp and thereafter filtered 
using shape and electrostatics-based matching as well as the above-mentioned 
pharmacophore model. 
 
The docking of the conformers of compounds in Libraries A and C was conducted 
using the FRED (Fast exhaustive docking) 
331
 module of the OpenEye software suite. The 
dengue RdRp structure was prepared using the MAKE_RECEPTOR program. It is a 
graphical utility for creating or modifying a receptor. The goal is to define a box enclosing 
the active site. The box should enclose the entire region active site where heavy atoms of the 
docking ligand can be placed. Any docked pose with any heavy atom that lies outside the box 






For the docking of Library A compounds into the GTP binding site, the center of the 
box was selected as the geometric mean of the entire dengue RdRp structure. The geometric 
mean was used because the site of interest was located in the middle of the dengue RdRp 
structure. The length and width of the box were 28 Å each, i.e. 14 Å from the center in four 
directions. For the docking of Library C compounds into the allosteric site of the in-house 
dengue RdRp crystal structure, the center of the box was selected as the geometric mean of 
the allosteric ligand. The length and width of the box were 16 Å each, i.e. 8 Å from the center 
in four directions. After visual inspection, those dimensions are deemed to adequately enclose 
the active site and the allosteric site respectively. The in-house dengue RdRp crystal structure 
used for docking had a backbone RMSD of 0.8Å compared to the corresponding structure 
(PDB: 2J7W) available at the Protein DataBank. This indicates that both crystal structures are 
extremely similar to each other and that they can be used for comparison of docking results. 
 
Next, consensus scoring of docked poses using 7 scoring functions was carried out. 
This was implemented by summing up the scores from the 7 scoring functions. The scoring 
functions that were used are summarised in Table 4.2.  




Shapegauss A shape-based scoring function that uses smooth Gaussian functions to 
represent the shapes of molecules. 
PLP 
 
Piecewise Linear Potential. 
Chemgauss A scoring function, which uses smooth Gaussian functions to represent the 
shape and chemistry of molecules. 




OEChemscore An OpenEye variant of Chemscore which is similar to the Chemscore 






Screenscore Implemented as described in reference [
51
]. 
Zapbind A scoring function which uses PB electrostatic calculations in combination 
with an area contact term. 
  
4.2.2 THE FIRST APPROACH 
 
 Five thousand top-ranked compounds based on the consensus scores were selected as 
Library A. It was analyzed using the Protein Ligand Interaction Fingerprint (PLIF) feature in 
Molecular Operating Environment (MOE).
186
 The PLIF tool is a method for summarizing the 
interactions between ligands and proteins using a fingerprint scheme. Interactions such as 
hydrogen bonds, ionic interactions and surface contacts are classified according to the residue 
of origin, and built into a fingerprint scheme. The BitSelector function of PLIF was used to 
identify amino acid residues that contributed an overall abundance of interactions ≥ 5%. The 
overall abundance is the frequency of occurrence of a particular fingerprint bit throughout the 
database. If the fingerprint bit occurs in every compound, the value will be 100.  
 In the BitSelector function of PLIF, there are 16 types of residue-ligand interactions 
named by the following rules: The first layer of this division consists of four elements and 
they are: side chain (Ch), backbone (Bk), solvent (Sv), or proximity (Ionic or Surf). Similarly, 
the second layer consists of two elements: hydrogen bond donor (Don), or acceptor (Acc) in 
the case of side chain, backbone, and solvent as a first layer but; ion and surface, in the case 
of proximity. Lastly, the third layer consists of two elements; low (1) or high (2). Hence the 
result of PLIF becomes 16 bits (422 = 16). The naming convention comes from this 





ACCeptor. The value 1 or 2 after the name represents a weak interaction (1) or a strong 
interation (2) so BkDon1 means BacKbone and DONer weak interaction. 
 
The probability of each residue identified in the previous step interacting with each 
compound in Library A was recorded and summed to obtain the PLIFScore. The compounds 
in Library A were then ranked according to their PLIFScores and the 100 top-ranked 
compounds were sent for the primary screen. Separately, another 100 compounds that 
interacted with Ser710, Arg729, Arg737, Thr794 and Ser796 were sent for another primary 
screen against Dengue RdRp. In the crystal structure, these five residues were shown to 
interact with 3'dGTP (Figure 4.3).  
 
Figure 4.3 Residues Ser-710, Arg-729, Arg-737, Thr-794, Trp-795, and Ser-796, which are making contacts 
with 3'dGTP, are represented as sticks, and the distances to the α-, β-, and γ-phosphates are displayed. (Figure 














Library A, assembled according to the workflow described in the previous section, was 
used as the starting point for the second approach. A crystal structure of Compound 1 (N-
sulfonylanthranilic acid) bound to an allosteric binding pocket (IC50 = 0.35μM) of RdRp was 
available in-house. The conformers of Library A were read into the ROCS (Rapid Overlay of 
Chemical Structures) module of the OpenEye software suite for shape-matching to dengue 
RdRp bound conformation of Compound 1 in the in-house crystal structure. Each conformer 
of each compound in Library A is overlaid rigidly on Compound 1 (the query molecule), and 
the overlap of molecular volume between Compound 1 and the Library A conformer is 
optimized. Then, a measure of shape similarity between them (the shape Tanimoto coefficient) 
is calculated. Once all conformers of the Library A compound have been overlaid and the 
shape Tanimoto has been calculated, the conformer with the highest shape Tanimoto (highest 
shape similarity) is saved, along with the overlay of that conformer with Compound 1. The 
output of ROCS was a set of 500 hits which were most similar in terms of shape to the bound 
conformation of Compound 1. Those 500 hits are then named Library B. In the next step, all 
the Library B compounds were then re-ranked using OpenEye EON module which compared 
the electrostatics potential maps of pre-aligned compounds and generated Tanimoto measures 





the structures. Electrostatic interactions play a major role in determining protein-ligand 
binding specificity as well as the rate of protein-ligand association. The complementarities of 
the electrostatic potential between the ligand and the binding pocket is an important factor in 
protein-ligand interactions. 
108, 109, 334-336
 The electrostatic free energy ΔGelectrostatic of binding 
represents an integral part of the free energy of binding ΔGbind. ΔGelectrostatic is often 
decomposed into favourable Coulumbic energy and an unfavourable desolvation penalty 




 has experimentally determined the IC50 values of Compound 1 and its 
20 analogues (Compounds 2-21) against dengue RdRp. Their IC50 values ranged from 
0.26μM to >20μM. Compounds 2-21 were flexibly aligned to Compound 1 (template) using 
the Flexible Alignment module in MOE 
186
. A three-dimensional 4-feature pharmacophore 
was generated (Figure 4.5) by the MOE Pharmacophore Elucidator 
186
 using the aligned 
structures and their corresponding IC50 values. The pharmacophore generated was used to 
sieve through the 500 hits which were re-ranked by OpenEye EON in the previous step. Hits 
that mapped to the pharmacophore (at least 3 features) were labelled putative ‘actives’ and 






Figure 4.5 Four-feature pharmacophore. ConfHit-1 (IC50 = 0.80 µM, depicted as grey cloud form), mapped to 
three features of the pharmacophore. 
 
4.2.4 THE THIRD APPROACH 
Library C was assembled according to the workflow described in the second approach 
except that the compounds were docked into the allosteric site as identified in the in-house 
crystal structure (Figure 4.2) instead of the GTP binding site. Library C was used as the 
starting point for the third approach. The output of ROCS was a set of 500 hits which were 
most similar in terms of shape to the bound conformation of Compound 1. In the next step, 
the 500 hits were then re-ranked using OpenEye EON module which compared the 
electrostatics potential maps of pre-aligned compounds and generated Tanimoto measures for 
comparison. The pharmacophore generated was used to sieve through the 500 hits which 
were re-ranked by OpenEye EON in the previous step. Hits that mapped to the 
pharmacophore (at least 3 features) were labelled putative ‘actives’ and were shortlisted for 






Figure 4.6 Virtual screening workflow using the Third Approach. 
 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 THE FIRST APPROACH: PLIF SCORING METHODS 
 
Table 4.3 Fourteen Hit compounds from the primary screen. 
Compounds IC50 (M) Hill Slope  Selected? 
PSHit01 8.49 -4.77 No 
PSHit02 2.74 -1.83 No 
PSHit03 12.30 -1.81 No 
PSHit04 12.10 -1.40 Yes 
PSHit05 25.30 -1.35 No 
PSHit06 18.00 -1.27 No 
PSHit07 15.80 -1.12 No 
PSHit08 11.80 -1.10 Yes 
PSHit09 6.33 -1.08 Yes 
PSHit10 16.60 -0.90 Yes 
PSHit11 27.90 -0.71 No 
PSHit12 7.77 -0.58 No 
PSHit13 7.55 -0.53 No 






Putative ‘actives’ from the BitSelector criteria of PLIF did not produce any hits in the 
experimental primary screen. One possibility could be that the GTP binding site was too large 
and extensive such that the residues which BitSelector identified were not located in close 
proximity of one another. The RNA template is located in the GTP binding pocket as 
described in the introduction of this chapter. The crystal structure is without the RNA and 
hence the active site is artificially large and therefore does not allow the BitSelector method 
to select the predicted hits. However, putative ‘actives’ that have interactions with residues 
Ser710, Arg729, Arg737, Thr794 and Ser796 produced 14 hits in the primary screen. Four 
active compounds were selected from these hits for Structure Activity Relationship (SAR) 
expansion expansion as highlighted in Table 4.3. The selection was conducted based on a 
balance between IC50 and Hill Slope values. The preferred Hill Slope values are 1.5 since 
compounds with Hill Slope values above 2 are generally thought to exhibit ligand 
aggregation 
338
 and hence, potentially false positives. In addition, compounds from the 
company archive, which are super structures (the converse of substructures) of the 4 selected 
primary screen hits, were sent for reconfirmation tests. None of those compounds and their 
respective super structures was active in the reconfirmation tests. It is not uncommon for 
primary screen hits to fail to ‘reconfirm’ since the primary inhibition assay was conducted at 
a single concentration of the compound instead of multiple concentrations in the case of 
reconfirmation tests. 
 
4.3.2 LIBRARY SCREENING & PHARMACOPHORE GENERATION 
 
57 hits from Library B matched at least 3 of the 4 pharmacophore features and were 





putative actives, there was 1 confirmed hit (ConfHit-1, Figure 4.7) which had IC50 value of 
0.80 µM. This compound was a promising hit for the lead identification phase of drug 
discovery. 
  
Figure 4.7 One confirmed hit emerged from a docking protocol that targeted the GTP binding site of dengue 
RdRp. 
 
98 hits from Library C matched at least 3 of the 4 pharmacophore features and were 
sent for testing in the dengue RdRp assay. The enzyme assay determined that of the 98 
putative actives, there were 2 Confirmed Hits (ConfHit-2 and ConfHit-3, Figure 4.8) which 
had IC50 values of 3.53 µM and 7.32 µM respectively. The structural scaffolds of these 2 
Confirmed Hits were vastly different from one another as well as ConfHit-1. 
 
In their recent work, Oliver et al. presented a comprehensive study of the influence of 
ensemble size on virtual screening and pose prediction. 
339
 They found that using ensembles 
of proteins performs better than the worst single protein structure. They recommended using 
multiple protein structures in an ensemble docking protocol in order to minimize the risk of 






One key structural feature of protein-ligand complexes is the presence of water which 
forms a complex hydrogen-bonding network between ligand and protein. In one study, 
340
 as 
much as 85% of 392 protein-ligand complexes had at least one water molecule bridging the 
protein-ligand interactions. Traditionally, ligands were docked into de-solvated binding sites 
by either ignoring or removing ordered water molecules. This was the approach used in the 
virtual screening workflow discussed in this chapter. It is a major limitation. However, it has 
also been reported that the prediction of a ligand’s correct binding mode may be hampered by 
including water molecules. 
341 
 
There is also a continuing inability of docking-based methods to identify actives as top 
of the identified lists. This is because the scoring functions used in current docking programs 
are still unable to accurately predict the free energy of binding. The scoring functions merely 














The virtual screening workflows in the second and third approaches have resulted in the 
identification of 3 Confirmed Hits that could serve as starting points for lead selection as well 
as SAR expansion. Surprisingly, the Confirmed Hits resulting from docking into the allosteric 
site (Library C) did not have IC50 values that were better than those derived from docking 
into the GTP binding site (Library B). The use of the pharmacophore based on the allosteric 
site should have identified compounds that have similar binding interactions to Compound 1 
(Figure 4.7) and hence they should have similar IC50 values to Compound 1 (at IC50 = 0.7M). 
It is also interesting to note that the IC50 values of ConfHit-2 and ConfHit-3 (Figure 4.8) fell 
within the same range as those of the 21 published compounds that were used to elucidate the 
pharmacophore model in spite of having strikingly different structural scaffolds. Tentatively, 
this may hint that ConfHit-2 and ConfHit-3 bind to the allosteric site but further assays using 
site-directed mutagenesis at the allosteric site of the dengue RdRp are required for 
confirmation. ConfHit-1 from Library B bore little structural resemblance to the two 
Confirmed Hits from Library C, which was anticipated as it was proposed to bind to a 
different binding site (GTP). In conclusion, the virtual screening workflows have served to 
filter a large compound library of 2 million compounds to tractable numbers (less than 5) 
which have been identified as confirmed hits by subsequent in vitro determinations. The 
putative hit compounds for the allosteric site were particularly interesting because they may 
illustrate a successful instance of “scaffold hopping” in view of their diverse scaffolds which 
bore limited resemblance to existing allosteric RdRp inhibitors but retaining the same level of 
inhibitory activity as these compounds. 
 
After a lead compound has been identified, modifications to its chemical structure are 





usually a need to synthesize a significant number of compound analogues. In the next chapter, 
a method is proposed in an attempt to provide a systemic approach to reducing the number of 







CHAPTER 5 EXPLORATION AND OPTIMIZATION OF 
STRUCTURE-ACTIVITY RELATIONSHIPS IN DRUG 




In the exploration of structure-activity relationships (SAR), current approaches are still 
heavily influenced by intuition and serendipity. A common approach to lead optimization in 
drug discovery is to vary one substitution site at a time while keeping other sites in the 
molecule unchanged. This approach is described as the “one-factor-at-a-time” (OFAT) 
technique and is based on the underlying assumption that the effect of each substituent is 
“isolated” from that of other substituents – that is, its effect on the biological response is 
independent of responses elicited by substituents at other sites of the molecule. Accordingly, 
the design of analogues involving multiple substitution sites cannot be handled efficiently by 
the OFAT approach. For example, if the optimum group at one substitution site has been 
determined, one cannot assume that it will still be the preferred group when changes are made 
to other sites. Under such circumstances, it is said that there are interactions between the 
substitution sites. The problem with the OFAT approach is that it does not readily identify 
such interactions. Furthermore, OFAT is likely to overlook certain combinations of groups at 
the substitution sites. Thus, some compounds (‘blind spot’ compounds, Figure 4.1) will not 
be synthesized or evaluated for biological activity. The question can then be asked if the 
choice of groups at each site in those compounds that are synthesized is indeed optimal, and 
hence if the resulting structure-activity relationships have been correctly deduced. The 
decision-making approach adopted in OFAT tends to be subjective and may overlook the 
optimal compound. The true SAR landscape is a combinatorial expansion of all the R-groups 





systematic exploration of the entire landscape are often overwhelming. Here, we propose a 
novel application of the Taguchi Method as an alternative approach to the optimization of 
chemical modifications to a core structure.  
 
Figure 5.1 The typical workflow of lead optimization using the one-factor-at-a-time (OFAT) approach. The 
OFAT approach often leads to ‘blind spot’ compounds that are not synthesized or investigated for their 
biological activities. 
 
5.2 ONE-FACTOR-AT-A-TIME EXPERIMENTS 
 
Table 5.1 The ‘strict’ OFAT design. 
Compound Position A Position B Position C 
1 1 1 1 
2 2 1 1 
3 2 2 1 
4 2 2 2 
5 2 1 2 
6 1 1 2 
7 1 2 2 
8 1 2 1 
 
One Factor 














The OFAT method of experimentation is one in which one factor is varied while all 
other factors remained unchanged at a specific set of conditions. The procedure is repeated in 
turn for all factors. There are 2 main types of OFAT designs: (1) the ‘strict’ OFAT and (2) 
the adaptive OFAT. 









1 1 1 1 6.0 
2 2 1 1 5.8 
3 1 2 1 0.1 
4 1 2 2 0.2 
 
The ‘strict’ OFAT design is one in which only one factor is varied between 
consecutive experiments. An example is given in Table 5.1. In adaptive OFAT design (Table 
5.2), the first compound is designed using the factor levels set to baseline (Level 1). In turn, 
each factor is changed to the previously untested level while all other factors remain 
unchanged. The level at which a particular factor gave an improved response is retained. The 
adaptive OFAT is therefore the version that medicinal chemists are most familiar with. It 
requires n + 1 compounds to be synthesized if there are n factors with 2 levels each. However, 
it cannot account for interactions between the factor levels. Moreover, using the adaptive 
OFAT method does not ensure that the optimal factor level settings are obtained since not all 
the possible factor level settings have been tested. Figure 4.1 illustrates adaptive OFAT and 
the possibility of missing some ‘blind spot’ compounds. 
 






The Taguchi Method, an approach based on Design of Experiments (DoE), 
342
 is 
widely used in the manufacturing industry for quality engineering purposes. In DoE, a design 
matrix is constructed in a combinatorial fashion that specifies the levels for several different 
factors for each experiment. A key feature of the Taguchi Method is the orthogonal array 
343-
345
 which is a pre-defined table specifying factors and levels. The simplest array (L4) is used 
to design experiments involving three factors with two levels per factor. In the lead 
modification context, an L4 array would investigate three substitution sites with two different 
substituents per site. In order to investigate interactions between sites and groups, four 
“experiments” (equivalent to synthesized compounds) are necessary. The choice of the size 
of the array of the initial compounds is directly determined by the number of substituent sites 
and the number of R-groups to be substituted at each site. The inventor of the Taguchi 
method has pre-determined sets of orthogonal arrays which prescribe which array of what 
size to use given the number of substituent sites and the number of R-groups to be substituted 
at each site. 
 
To evaluate the optimal variable settings, the Taguchi Method recommends the use of 
the loss function as a means of monitoring the deviation in the quality characteristic. In the 
present context, the optimal variable settings are the preferred functionalities at the 
substitution sites, and the quality characteristic is the biological response elicited by the test 
compound, as reflected by its half maximal concentration (IC50) required to reduce the 
response under study (specific binding or enzyme activity or cell viability) to 50% of that 
observed in the absence of the test compound (Table 5.3). Here the desired outcome of lead 
optimization is to reduce the magnitude of the quality characteristic (“lower-the-better”) since 











Factor Substitution site 
Controllable variables that influence the characteristic function or 
biological response. They can be modified to optimize the 
performance of the system or molecule. 
Level Functional group 
The values that a factor can have or the functional group that can be 




(IC50 or EC50) 
The response or output of the system that is to be maximized or 
minimized, depending on which option gives the most favorable 
biological outcome.  
 
The deviation in the half-maximal concentrations is monitored as the signal-to-noise 
(S/N) ratio. As this ratio measures the “noise” arising from repeated determinations of the 
half-maximal concentrations, a more positive/less negative value is desired. The S/N ratio ηs 

















10log10)(ratio S/N     (1). 
 In Equation 1, yij is the IC50 or EC50 value of the i-th replicate of the j-th compound 
and the summation i extends over the number of replicate measurements, n. Table 5.4 
illustrates this process for the L4 Taguchi array.  
 
Once the S/N ratios are determined for the compounds in the array, the next step is to 
evaluate the contributions (average effects) of the functional group (1 or 2) at the specific 
substitution position. For instance, to determine the contribution of group 1 at position A (A1), 
the S/N ratios of compounds 1 and 2 are averaged since only these compounds (and not 





contribution of group 2 at position C (C2) is obtained from the average S/N ratios of 
compounds 2 and 3 and so on (Table 5.5). 
 
Table 5.4 The L4 orthogonal array of the Taguchi Method. Briefly, each compound is modified at 3 positions (A, 
B, C) and at each position two substitutions (1 or 2) are made. 
Compound Position A Position B Position C 
IC50 
S/N ratio 
Replicate 1 Replicate 2 
1 1 1 1 y1,1 y2,1 η1 
2 1 2 2 y1,2 y2,2 η2 
3 2 1 2 y1,3 y2,3 η3 
4 2 2 1 y1,4 y2,4 η4 
 
Table 5.5 Calculation of the average effects of each factor and corresponding levels using the Taguchi Method. 
 Position A Position B Position C 
Group 1 (η1+ η2)/2 (η1+ η3)/2 (η1+ η4)/2 
Group 2 (η3+ η4)/2 (η2+ η4)/2 (η2+ η3)/2 
Difference |A1A2| |B1B2| |C1C2| 
 
After calculating the contribution (mean S/N ratio) of each group at its corresponding 
position (Table 5.5), the mean S/N ratios of all groups at that position are compared to 
determine the optimal group for that position. The preferred group is the one with the more 
positive S/N ratio. It should be noted that when IC50 or EC50 values have large variations, the 
S/N ratios will become more negative (Equation 1) and this would invariably influence the 
choice of the optimal R group which favours larger S/N ratios. Once the optimal R groups for 
the other substitution positions have been determined, it is now possible to predict the 





groups at each position. If this compound is not available, it must then be synthesized and 
evaluated. 
 
5.4 MATERIALS AND METHODS  
Datasets 
In this study, the application of the Taguchi method in identifying the optimal 
compound for 4 datasets is presented. There are significant difficulties in identifying suitable 
public datasets because the medicinal chemistry literature often does not report the full 
combinatorial set of compounds. Yet, for the purpose of applying the Taguchi Method to 
drug design, the complete set of compounds and their corresponding biological activities are 
essential. Here, we found three public datasets and developed one in-house dataset that could 
be used to address our objectives (Table 5.6). Dataset 1 is made up of 8 compounds selected 
from a series of curcuminoids which were evaluated for antioxidant activity using the DPPH 
(1,1-diphenyl-2-picrylhydrazyl) free radical-scavenging activity assay.
346
 Antioxidant activity 
was quantified in terms of EC50 which is the concentration required to reduce the absorbance 
of the DPPH radical by 50%. Dataset 2 comprises 8 compounds selected from a cyclin-
dependent kinase 5 (CDK5)/p25 inhibitor discovery program. 
347
 Inhibition of CDK5 was 
measured by a scintillation proximity assay (SPA). Dataset 3 is made up of 8 functionalized 
benzopyrans identified as inhibitors of NADH: ubiquinone oxidoreductase (complex I). 
348
 
Inhibitory potency was determined using bovine heart electron transport particles (ETP). 
349
 
The method involved pre-incubating ETP with the test compound, after which NADH was 
added and the residual enzyme activity was determined by a spectrophotometric method. 
350
 
Dataset 4 comprises 16 compounds that were synthesized by the authors and evaluated for 







which are sensitive to all-trans-retinoic acid. Growth inhibitory IC50 (concentration required 
to reduce viability by 50% of control untreated cells) values were determined by a 
colorimetric tetrazolium (MTS) assay. 
 
Table 5.6 Scaffold of each dataset and the respective R-groups at each substitution site. 














CH3, C6H5 CH3, CH2Cl 
3 
 
H, OCH3 H, OCH3 H, OCH3 
4 
 
H, OH H, OH CH2, S 
H, OCH3 H, OCH3 CH2, S 
 
Based on the available compounds in Dataset 1 
346
 (Table 5.7a), we have arbitrarily 
assigned H as Level 1 and acetoxy as Level 2 at position R
1
, H and methoxy as Levels 1 and 
2 respectively at position R
2
, and hydroxyl and methoxy as Levels 1 and 2 at position R
3
 
(Table 5.7b). The L4 array for Dataset 1 was then constructed (Table 5.7c) and comprises 7e, 
7b, 8n and 8i. Their EC50 values for free radical scavenging activity were converted to S/N 
ratios according to Equation 1. Noting that EC50 values were cited as mean ± confidence 
intervals (95%) in the report, values represented by the lower and higher confidence limits (2 





interval was not reported, possibly due to the absence of activity even at the highest test 
concentration, the S/N ratio was obtained from the mean value. Thereafter, the contribution 






 was assessed from its S/N ratio.  
 
Table 5.7 Dataset 1: a) The published EC50 values of all the compounds in Dataset 1 and the respective 
confidence intervals used in the calculation of the S/N ratio. b) Assignment of levels for each substitution site. c) 
















 Mean EC50 (µM) 
7e H H OH >100 
7b H OCH3 OCH3 >100 
8n OCOCH3 H OCH3 32.8 ± 1.6 
8i OCOCH3 OCH3 OH 8.7 ± 0.6 
8j OCOCH3 OCH3 OCH3 22.1 ± 2.7 
8m OCOCH3 H OH 26.3 ± 0.6 
7a H OCH3 OH 22.6 ± 2.3 









1 H H OH 








 Mean EC50 (µM) S/N ratio 
7e H H OH >100 40.0 





8n OCOCH3 H OCH3 32.8 ± 1.6 30.3 









Level 1 40.0 35.2 29.4 
Level 2 24.6 29.4 35.2 
Difference 15.4 5.8 5.8 
Preferred Level 2 2 1 





Mean EC50 = 8.7 µM 
Potency ranking = 1 out of 8 
 
Table 5.8 Dataset 1: a) Assignment of levels for each substitution site. b) L4 orthogonal array prescribing 
compounds to be synthesized and tested based on the Taguchi Method. The confidence intervals of the 
published EC50 values were used in the calculation of the S/N ratio since those of the replicates were not 















1 OCOCH3 OCH3 OCH3 








 Mean EC50 (µM) S/N ratio 
8j OCOCH3 OCH3 OCH3 22.1 ± 2.7 27.0 
8m OCOCH3 H OH 26.3 ± 0.6 28.4 
7a H OCH3 OH 22.6 ± 2.3 27.1 













Level 1 27.7 27.0 33.5 
Level 2 33.6 34.2 27.8 
Difference 5.9 7.2 5.7 
Preferred Level 1 1 2 
Corresponding group OCOCH3 OCH3 OH 
Optimal compound predicted 
 
Compound 8i 
Mean EC50 = 8.7 µM 
Potency ranking = 1 out of 8 
 
 
5.5 RESULTS AND DISCUSSION 





 = methoxy, R
3
 = hydroxyl. This combination of functional groups corresponds to 
compound 8i which has indeed the lowest mean EC50 value (most potent) of the eight 
compounds that would be analyzed if the full factorial design was implemented. In this case, 
the Taguchi Method successfully predicted the optimal compound based on the 4 compounds 
of the L4 array. We thought it is necessary to test the method on reassigning the levels, as our 
initial approach (assignment based on substituent group mass) was arbitrary and could have 
influenced the identification of 8i as the optimal compound. Hence, the assignments are 
reversed with the heavier acetoxy assigned to Level 2 (not Level 1) and H to Level 1 
(previously Level 2) at position R
1





array now consists of the previously left-out compounds, namely 8j, 8m, 7a and 7f (Table 
5.8b). If the method is stable, the same compound (8i) would be identified and this was 







 are acetoxy, methoxy and hydroxyl respectively, which correspond to 8i. Thus, 
the Taguchi Method has predicted the same optimal compound for Dataset 1 regardless of 
how the levels were assigned. 
 
Dataset 2 was investigated in the same way. Table 5.9a depicts the scaffold present in 
the target compounds of Dataset 2. Modifications are made at three positions on the scaffold: 
R
1
 (acetamide -NHCOCH3 or chloroacetamide -NHCOCH2Cl), R
2
 (methyl -CH3 or phenyl -
C6H5) and R
3
 (methyl -CH3 or chloromethyl -CH2Cl). We assigned the following groups as 








 = NHCOCH3, R
2
 = CH3 and R
3
 = CH3 based on their larger 
mass as in Dataset 1. The resulting L4 array proposes the synthesis and biological evaluation 
of 4 compounds (7z, 7v, 7ag, 7m) (Table 5.9b) instead of 8 compounds that would be 
required in a full factorial array. The remaining 4 compounds not identified by the L4 array 
were available in the original report 
347
 and used for validation purposes. 
 
Table 5.9 Dataset 2: a) Assignment of levels for each substitution site. b) L4 orthogonal array prescribing 
compounds to be synthesized and tested based on the Taguchi Method. The method recommends synthesis of 
compounds 7z, 7v, 7ag and 7m (numbered as they appear in 
347
) which comprise four of eight compounds 
arising from permutations of 2 groups at 3 positions (2
3
 = 8). The other compounds are 7u, 7y, 7n and 7ah 
(numbered according to reference 
347





















1 NHCOCH3 CH3 CH3 








 Mean IC50 (nM) S/N ratio 
7z NHCOCH3 CH3 CH3 384 ± 48 51.75 
7v NHCOCH3 C6H5 CH2Cl 643 ± 84 56.24 
7ag NHCOCH2Cl CH3 CH2Cl 462 ± 68 53.29 









Level 1 54.00 52.57 51.46 
Level 2 52.28 53.70 54.81 
Difference 1.72 1.13 3.35 
Preferred Level 2 1 1 





Mean IC50 = 354 nM 
Potency ranking = 1 out of 8 
 
As seen in Table 5.9c, the optimal compound is 7y which has the lowest IC50 value (most 
potent) among the eight compounds in the full factorial design. Thus, the Taguchi Method 
has correctly predicted the optimal compound from data derived from only four compounds. 
7y was not listed in the L4 array (Table 5.9b). As in Dataset 1, we went on to reassign the 





5.10a). The L4 array now consists of the previously left-out compounds, namely 7u, 7y, 7n 
and 7ah (Table 5.10b). S/N ratios were derived for the new L4 array and interestingly, 7y was 
again identified as the optimal compound (Table 5.10c).   
Table 5.10 Dataset 2: a) Assignment of levels for each substitution site; S/N ratios of the prescribed compounds. 

















1 NHCOCH2Cl C6H5 CH2Cl 








 Mean IC50 (nM) S/N ratio 
7u NHCOCH2Cl C6H5 CH2Cl 530 ± 64 54.55 
7y NHCOCH2Cl CH3 CH3 354 ± 43 51.04 
7n NHCOCH3 C6H5 CH3 542 ± 46 54.71 









Level 1 52.80 54.63 54.10 
Level 2 54.18 52.35 52.88 
Difference 1.38 2.28 1.22 
Preferred Level 1 2 2 









Mean IC50 = 354 nM 
Potency ranking = 1 out of 8 
In Dataset 3, the IC50 values for inhibition of NADH: ubiquinone oxidoreductase were 
reported as mean values with no confidence limits or standard errors (Table 5.11a). Thus S/N 
ratio for each compound was computed from the single mean value (n =1 in equation 1) 
which was not the case for Datasets 1 and 2. Based on the methodology described earlier, the 
optimal functional groups are R
1
 = methoxy, R
2
 = methoxy and R
3
 = H, which corresponds to 
compound 42 (Table 5.11c) which indeed has the lowest mean IC50 value among the eight 
compounds in the full factorial design. When the groups in Levels 1 and 2 were reassigned as 







 (Table 5.12c), which corresponds to compound 108. Here, reassigning the groups 
has resulted in a different optimal compound (108) which is the 2nd most potent compound 
in the array, with an IC50 of 330 nM compared to 220 nM for the most potent compound 42. 
Notwithstanding this difference, the compounds identified by the Taguchi Method are still 
highly ranked in terms of their potency. 
Table 5.11 Dataset 3: a) Assignment of levels for each substitution site; S/N ratios of the prescribed compounds. 





















1 H H H 








 Mean IC50 (nM) S/N ratio 
91 H H H 1700 64.61 
99 H OCH3 OCH3 530 54.59 
100 OCH3 H OCH3 1000 60.02 









Level 1 59.60 62.31 55.91 
Level 2 53.61 50.90 57.31 
Difference 5.99 11.41 1.40 
Preferred Level 2 2 1 





Mean IC50 = 220 nM 









Table 5.12 Dataset 3: a) Assignment of levels for each substitution site. b) L4 orthogonal array prescribing 

















1 OCH3 OCH3 OCH3 








 Mean IC50 (nM) S/N ratio 
108 OCH3 OCH3 OCH3 330 50.37 
98 OCH3 H H 830 58.38 
97 H OCH3 H 900 59.08 









Level 1 54.38 54.73 56.08 
Level 2 60.44 60.09 58.73 
Difference 6.06 5.36 2.65 
Preferred Level 1 1 1 










Potency ranking = 2 out of 8 
 
 
The in-house Dataset 4 
352
 is depicted in Table 5.13. Here, modifications were made 
at the central ring and two positions (meta, para) of rings A and B which have the same 
substituent groups. The central ring is either cyclohexanone (R
3
 = CH2) or thiopyranone (R
3
 = 




) are H, hydroxyl (OH) or methoxy (OCH3). To 
accommodate the 3 permutations on rings A/B as compared to 2 modifications of the central 
ring two L4 arrays are proposed. In the 1st L4 array (Configuration 1, Table 5.13b), the ring 
substituents are H or OH and in the second L4 array (Configuration 2, Table 5.15b), they are 
H or OCH3. In both Configurations 1 and 2, the central ring is either cyclohexanone or 
thiopyranone (Table 5.13a, 5.15a). The L4 arrays require the synthesis and biological 
evaluation of 8 compounds (4 for each array: Table 5.13b, 5.15b) out of the 16 compounds 
required in a full factorial design. The remaining 8 compounds were also synthesized and 
evaluated to validate the L4 array (Table 5.14a, 5.16a). Groups are assigned to Levels based 
on their molecular masses, as in the case of the earlier datasets.  
Table 5.13 Dataset 4: a) Assignment of levels for each substitution site. b) S/N ratios for the prescribed 
















1 H H CH2 














 Mean IC50 NB4 (µM) S/N ratio 
1 H H CH2 4.50 ± 0.42 13.08 
12 H OH S 2.52 ± 0.22 8.07 
13 OH H S 0.51 ± 0.07 5.78 









Level 1 (H) 10.58 (H) 3.65 (CH2) 11.10 
Level 2 (OH) 1.66 (OH) 8.59 (S) 1.15 
Difference 8.91 4.94 9.95 
Preferred Level 2 1 2 





Mean IC50 NB4 = 0.51 ± 0.07µM 
Potency ranking = 1 out of 8 
 
 The same procedure was applied to the two arrays. Unlike the earlier datasets, 
replicate growth inhibitory IC50 values were obtained for the compounds and these were used 
to compute the S/N ratios. Table 5.13c shows the results obtained for Configuration 1. Here, 






 are OH, H and S respectively, which 
correspond to Compound 13. Compound 13 does indeed have the lowest mean IC50 value 





Table 5.14 Dataset 4: a) Assignment of levels for each substitution site. b) S/N ratios for the prescribed 
















1 OH OH S 
2 H H CH2 
b) 
 







 Mean IC50 NB4 (µM) S/N ratio 
8 H OH CH2 2.50 ± 0.11 7.97 
9 OH H CH2 0.98 ± 0.06 0.17 
14 H H S 1.19 ± 0.23 1.63 









Level 1 (OH) 6.65 (OH) 10.72 (S) 7.55 
Level 2 (H) 4.80 (H) 0.73 (CH2) 3.90 
Difference 1.85 9.99 3.65 
Preferred Level 2 2 2 





Mean IC50 NB4 = 4.50 ± 0.42µM 






As before, the groups at Levels 1 and 2 were reassigned (Table 5.14a) and compound 
1 was identified as the optimal compound (Table 5.14c). This prediction is clearly flawed as 
Compound 1 (IC50: 4.50 µM) is ranked a lowly 7th among the 8 compounds in the full 
factorial design. In the case of Configuration 2 (Table 5.15a), the Taguchi Method identified 
Compound 7 (R
1
 = OCH3, R
2
 = H, R
3
 = CH2) to be optimal (Table 5.15b). However this is 
again a questionable prediction as compound 7 (IC50: 6.24 µM) is ranked among the less 
potent compounds.  
 













 of Configuration 2 and the predicted optimal 










1 H H CH2 








 Mean IC50 NB4 (µM) S/N ratio 
1 H H CH2 4.50 ± 0.42 13.08 
4 OCH3 OCH3 CH2 4.01 ± 0.24 12.07 
10 H OCH3 S 17.19 ± 4.53 24.84 













Level 1 (H) 18.96 (H) 10.63 (CH2) 12.57 
Level 2 (OCH3) 10.12 (OCH3) 18.45 (S) 16.51 
Difference 8.84 7.82 3.93 
Preferred Level 2 1 1 





Mean IC50 NB4 = 6.24 ± 0.49 µM 
Potency ranking = 6 out of 8 
 
Re-assigning the groups to a different level gave the L4 array shown in Table 5.16b, 
and in this case, compound 11. (R
1
 = OCH3, R
2
 = H, R
3
 = S) was identified. In terms of 
growth inhibitory potency, Compound 11 (IC50: 2.51 µM) is ranked 3rd among the 8 
compounds in the full factorial array.  
Table 5.16 Dataset 4: a) Assignment of levels for each substitution site. L4 orthogonal array prescribing 
compounds to be synthesized and tested based on the Taguchi Method. b) S/N ratios for the prescribed 






 of Configuration 2 and the predicted optimal compound. IC50 










1 OCH3 OCH3 S 












 Mean IC50 NB4 (µM) S/N ratio 
6 H OCH3 CH2 19.56 ± 1.53 25.84 
7 OCH3 H CH2 6.24 ± 0.49 15.96 
14 H H S 1.19 ± 0.23 1.63 









Level 1 (OCH3) 6.38 (OCH3) 11.32 (S) 0.79 
Level 2 (H) 13.73 (H) 8.79 (CH2) 20.90 
Difference 7.35 2.52 21.69 
Preferred Level 1 2 1 





Mean IC50 NB4 = 2.51 ± 0.28 µM 
Potency ranking = 3 out of 8 
 
The objective of this investigation is to assess the suitability and illustrate the 
application of the Taguchi Method as an alternative to the OFAT approach that is widely 
used by medicinal chemists to interrogate the choice of functional groups to be introduced at 
multiple sites of a lead scaffold. We speculated that the DoE approach that is intrinsic to the 
Taguchi method would permit monitoring of interactions between substituent groups (factors), 
analogous to its ability to address the interactions that are present between operating 





address one of the shortfalls of the OFAT approach and notably, to achieve this end in a more 
cost-effective manner. 
To examine this hypothesis, we applied the Taguchi Method to four datasets of 
compounds, three of which are obtained from reported literature and another which is an in-
house dataset. With the Taguchi Method, the choice of the best groups at each position may 
be reached by considering 4 compounds instead of the usual 8 that would be required if 
permutations are made at all 3 positions. For Dataset 1, the antioxidant activity was 
determined by a chemical reaction between DPPH and the test compound. In the case of 
Datasets 2 and 3, compounds were assessed for their ability to inhibit target enzymes using in 
vitro assays. Unlike the other Datasets, the compounds in Dataset 4 were evaluated for 
growth inhibitory activity on a cell based assay. The specific protein(s) targeted by these 
compounds in the assay is not known. 
 The results show that the Taguchi Method correctly predicted the most potent 
compound for Datasets 1 and 2. That the outcomes are not influenced by our arbitrary 
assignment of groups to the different levels is confirmed when the same compound was 
identified upon reassignment of the groups. In the case of Dataset 3, the Taguchi Method also 
correctly identified the most potent compound. When the groups were re-assigned to give a 
different L4 array, the method identified the 2nd most potent compound which is still an 
acceptable outcome.  
For Datasets 1-3 where the Method was able to identify the optimal compound, we 
noted that this was achieved under the following conditions: (i) the same set of compounds 
were prescribed regardless of the order in which the substitution sites are assigned to 
particular columns in the orthogonal arrays. (ii) For Datasets 1 and 2, the Method predicted 





the orthogonal array. (iii) Levels were arbitrarily assigned based on molecular mass. Whether 
assignment based on other criteria (such as lipophilicity, dipole moment) or in a less 
structured manner (for instance, Level 1 for R
1
= low molecular mass group while Level 1 for 
R
2
 = high molecular mass group) would still give the same outcome is an area that should be 
considered.  
We are less successful when the Method was applied to Dataset 4. For that dataset, we 
constructed two L4 arrays which are identified as Configuration 1 and Configuration 2. The 
Taguchi Method ironically identified the least active compound for Configuration 1, and on 
reassigning the groups, the method predicted the second least active compound. For 
Configuration 2, the third least active compound was flagged out and on reassignment of 
groups; the third most active compound was highlighted.  
Another feature of the dataset that would influence the outcome of the Taguchi Method 
is the range of activities (IC50, EC50) of the member compounds. As in any method used for 
deducing SAR, a broad range (at least a fold magnitude) is desirable and this is determined in 
part by the intrinsic property of the compounds and the analytical capabilities (dynamic range) 
of the assay method. Of the four datasets used for analysis, Datasets 1 and 4 have decent 
dynamic ranges (at least 10 fold, 40 fold respectively) while Datasets 2 and 3 have narrower 
ranges (2 fold and 3 fold respectively). Although we were able to illustrate the validity of the 
Method with Datasets 2 and 3, it is preferable to work with datasets with wider activity 
ranges to ensure reliable predictions.  
Table 5.17 Comparison of full factorial design and the Taguchi Method. 





2 2 4 (= 2
2
) 4 
2 3 9 (= 3
2
) 9 













In the present investigation, we have illustrated the application of the method to lead 
modification using the L4 array which is the simplest orthogonal array. In practice, lead 
modification will involve changes at more positions than that specified by the L4 array. Such 
changes will lead to an increase in the number of compounds that need to be evaluated. The 
strength of the Taguchi Method is its ability to reduce the number of compounds required for 
synthesis and evaluation. As shown in Table 5.17, the maximum number of required 
experiments is substantially lower than in a full combinatorial design. The full potential of 
the Taguchi Method is best realized in datasets with multiple substitution positions (“factors”) 
and different groups (“levels”) assigned to each position. For example in the case of datasets 
with three substitution sites and three R-groups at each site, 27 compounds are required for a 
thorough analysis of the SAR as compared to only 9 compounds using the Taguchi approach. 
The reduction in number of compounds and the economic savings arising from it are key 
advantages of this approach. Even if it is not used to identify the optimal compound, the 
Method may be applied to shortlist second-priority compounds (of lower potency). This may 
be achieved by picking two of the R positions with the best S/N ratio and selecting the R-
group with the second highest S/N ratio for the remaining third position. By repeating this 
process for each of the three R positions, second-priority compounds are thus proposed. The 
3 3 27 (= 3
3
) 9 
3 4 64 (= 4
3
) 16 
4 2 16 (= 2
4
) 8 
4 3 81 (= 3
4
) 9 
4 4 256 (= 4
4
) 16 





usefulness of these compounds should not be under-rated as they may become important 
when more potent analogues fail to meet expectations due to poor drug-like features. One 
limitation of the Taguchi approach is that it is only able to make use of the R-groups given in 
the array. In other words, the effect of the novel substituents that have not been included 
cannot be predicted by the Taguchi method. 
 
Table 5.18 Logical optimization paths for Dataset 1. The best compound is indicated with a  symbol. 
(a) 
Dataset 1 
Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
8m OCOCH3 H OH 26.3 
8i OCOCH3 OCH3 OH 8.7  




Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
8m OCOCH3 H OH 26.3 
8n OCOCH3 H OCH3 32.8 
8i OCOCH3 OCH3 OH 8.7  




Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7f H H OCH3 >100 
8m OCOCH3 H OH 26.3 
8i OCOCH3 OCH3 OH 8.7  




Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7f H H OCH3 >100 
7a H OCH3 OH 22.6 
8i OCOCH3 OCH3 OH 8.7  




Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7f H H OCH3 >100 
8n OCOCH3 H OCH3 32.8 
(f) 
Dataset 1 
Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7f H H OCH3 >100 





8j OCOCH3 OCH3 OCH3 22.1 
 
8n OCOCH3 H OCH3 32.8 







Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7f H H OCH3 >100 
7b H OCH3 OCH3 >100 
8n OCOCH3 H OCH3 32.8 







Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7a H OCH3 OH 22.6 
7b H OCH3 OCH3 >100 
8i OCOCH3 OCH3 OH 8.7  




Compound R1 R2 R3 Mean EC50 (M) 
7e H H OH >100 
7a H OCH3 OH 22.6 
8i OCOCH3 OCH3 OH 8.7  




Table 5.19 Logical optimization paths for Dataset 2. The best compound is indicated with a  symbol. 
(a) 
Dataset 2 
Compound R1 R2 R3 Mean IC50 (nM) 
7z NHCOCH3 CH3 CH3 384 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 




Compound R1 R2 R3 Mean IC50 (nM) 
7z NHCOCH3 CH3 CH3 384 
7y NHCOCH2Cl CH3 CH3 354  
7ag NHCOCH2Cl CH3 CH2Cl 462 




Compound R1 R2 R3 Mean IC50 (nM) 
(d) 
Dataset 2 





7z NHCOCH3 CH3 CH3 384 
7n NHCOCH3 C6H5 CH3 542 
7ah NHCOCH3 CH3 CH2Cl 476 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 
7ag NHCOCH2Cl CH3 CH2Cl 462 
 
7z NHCOCH3 CH3 CH3 384 
7n NHCOCH3 C6H5 CH3 542 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 




Compound R1 R2 R3 Mean IC50 (nM) 
7z NHCOCH3 CH3 CH3 384 
7ah NHCOCH3 CH3 CH2Cl 476 
7n NHCOCH3 C6H5 CH3 542 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 




Compound R1 R2 R3 Mean IC50 (nM) 
7z NHCOCH3 CH3 CH3 384 
7ah NHCOCH3 CH3 CH2Cl 476 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 




Compound R1 R2 R3 Mean IC50 (nM) 
7z NHCOCH3 CH3 CH3 384 
7ah NHCOCH3 CH3 CH2Cl 476 
7n NHCOCH3 C6H5 CH3 542 
7y NHCOCH2Cl CH3 CH3 354  
7m NHCOCH2Cl C6H5 CH3 356 










Table 5.20 Logical optimization paths for Dataset 3. The best compound is indicated with a  symbol. 
(a) 
Dataset 3 
Compound R1 R2 R3 Mean IC50 (nM) 
91 H H H 1700 
98 OCH3 H H 830 
42 OCH3 OCH3 H 220  




Compound R1 R2 R3 Mean IC50 (nM) 
91 H H H 1700 
97 H OCH3 H 900 
42 OCH3 OCH3 H 220  




Compound R1 R2 R3 Mean IC50 (nM) 
91 H H H 1700 
97 H OCH3 H 900 
99 H OCH3 OCH3 530 




Compound R1 R2 R3 Mean IC50 (nM) 
91 H H H 1700 
96 H H OCH3 1230 
100 OCH3 H OCH3 1000 




Compound R1 R2 R3 Mean IC50 (nM) 
91 H H H 1700 
96 H H OCH3 1230 
99 H OCH3 OCH3 530 









Table 5.21 Logical optimization paths for Dataset 4 Configuration 1. The best compound is indicated with a  
symbol. 
(a) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
9 OH H CH2 0.98 
5 OH OH CH2 2.79 
13 OH H S 0.51  
15 OH OH S 4.71 
 
(b) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
9 OH H CH2 0.98 
13 OH H S 0.51  
15 OH OH S 4.71 
 
(c) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
8 H OH CH2 2.50 
5 OH OH CH2 2.79 
12 H OH S 2.52 
15 OH OH S 4.71 
 
(d) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
8 H OH CH2 2.50 
12 H OH S 2.52 
15 OH OH S 4.71 
 
 (e) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
14 H H S 1.19 
13 OH H S 0.51  
15 OH OH S 4.71 
 
 (f) 
Dataset 4 Configuration 1 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
14 H H S 1.19 
12 H OH S 2.52 








Table 5.22 Logical optimization paths for Dataset 4 Configuration 2. The best compound is indicated with a  
symbol. 
(a) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
7 OCH3 H CH2 6.24 
6 H OCH3 CH2 19.56 
14 H H S 1.19 
 
(b) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
7 OCH3 H CH2 6.24 
14 H H S 1.19 
10 H OCH3 S 17.19 
 
(c) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
6 H OCH3 CH2 19.56 
7 OCH3 H CH2 6.24 
14 H H S 1.19 
11 OCH3 H S 3.68 
10 H OCH3 S 17.19 
 
(d) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
6 H OCH3 CH2 19.56 
14 H H S 1.19 
11 OCH3 H S 3.68 
10 H OCH3 S 17.19 
 
 (e) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
14 H H S 1.19 
11 OCH3 H S 3.68 
10 H OCH3 S 17.19 
 
 (f) 
Dataset 4 Configuration 2 
Compound R1 R2 R3 Mean IC50 (M) 
1 H H CH2 4.50 
14 H H S 1.19 
10 H OCH3 S 17.19 
11 OCH3 H S 3.68 
 
 
In order to compare the performance of the Taguchi method with the adaptive OFAT 
approach, all the possible Logical Optimization Paths (LOPs) that a typical medicinal chemist 
will take has been explicitly listed. The adaptive OFAT results (Figures 5.18 to 5.22) show 
that the choice of the second compound is critical in determining the number of compounds 





optimal compound was never found and that was exactly the situation (‘blind spot’ 
compound) that has been illustrated in Figure 5.1. Interestingly, for Dataset 4 Configuration 2 
(Figure 5.22), none of the six LOPs found the optimal compound. Coincidentally, the 
Taguchi method also failed to predict the optimal compound for this particular dataset. For 
those optimization paths that did find the optimal compound, it was usually found by the time 
at which the fourth compound was synthesized or earlier. However, since there are so many 
possible ways the optimization paths could have been carried out, the adaptive OFAT method 
is still largely dependent on intuition and serendipity.  
 
Each of the LOPs were equally possible, making a decision on which path to take can 
therefore be highly subjective. From the pragmatic (experimental) point of view, usually 
several compounds are sent collectively for biological assays. It is rare for a lone compound 
to be sent for assay testing before the next compound is synthesized. Therefore, the Taguchi 
method is relatively more pragmatic in the laboratory setting since it is able to suggest an 
array of compounds that can be sent collectively for assay testing. 
 
There are other examples of borrowing techniques from other fields and applying them 
for compound optimization. Very recently, there is a trend towards optimizing drug 
candidates for multiple objectives. Such multi-objective optimization methods 
353, 354
 
originated from the engineering and manufacturing industry. For example, in one study, 
355
 
from 1030 possible solutions, the authors were able to select a ligand with preferential 









Taken together, our preliminary findings have shown that the Taguchi Method may be 
a viable alternative to the OFAT approach of lead modification. However, the applicability of 
the method is strongly influenced by the nature of the biological evaluation and the 
characteristics of the dataset. It is more successful in those cases where activity is assessed 
against a known target (as in Datasets 2 and 3) or involves a specific chemical reaction 
(Dataset 1). In the case where activity is evaluated by a more complex cell-based system 
(Dataset 4), the method fails to meet expectations. Datasets with a reasonable range of 
measured activities and with small variability within individual determinations (small 
standard deviation) are preferable. In keeping with the hypothesis on which SAR 
optimization is based, investigations are on-going to confirm our preliminary conclusions and 






CHAPTER 6 CONCLUSION AND FUTURE WORK 
 
 
The aim of this thesis centred on investigating the various methodologies that can be 
applied for the selection and prioritization of compounds in drug discovery.  
 
The first part of this work has shown that the computational workflow comprising the 
Hopkins-based descriptor selection method and Random Forest Clustering has outperformed 
the conventional +3 method that is commonly used as the industry benchmark. Thus, it 
may be viewed as an alternative method that can be applied for the triaging of hit lists from 
high-throughput screening since it is able to handle non-Gaussian skewed datasets reasonably 
well. This work may be applied to the hit identification phase of drug discovery. However, a 
challenge that remains to be resolved is the memory requirement for large datasets. One 
possibility for future work will be to split the large datasets into subsets and process each of 
them separately before pooling the results together.  
 
Oftentimes, the initial generation of hit and lead compounds result in compounds that 
have undesirable liabilities. It is then necessary to identify and modify the groups or features 
associated with these liabilities, while preserving those substructures that are responsible for 
desirable potency. As such, the second part of this thesis has shown that the novel application 
of Correlation Rules to extract substructure profiles, i.e. a collective group of chemical 
substructures, has significant superiority when compared to classical similarity search 





enriching compound libraries or prioritizing compounds for evaluation against a specific 
therapeutic target. Future work may include extending this method beyond pair-wise activity-
fingerprint key correlations to correlating multiple fingerprint keys with activity. The use of 
the method as a virtual screen to enrich a compound library in a prospective manner would 
also be interesting. Perhaps more comparisons of the Correlation Rules approach to 
established Bayesian-based methods may be carried out. In addition, further investigations 
into the possibility of assigning a probability score to each compound may be performed as 
well. The probability score may serve as an intuitive indication of confidence of the 
prioritization computed via the Correlation Rules approach. 
 
In the third part of this thesis, the multi-step virtual screening workflow has led 
successfully to the identification of three hit compounds that possess in vitro activity against 
the dengue RNA-dependent RNA polymerase. Some of these hit compounds have a different 
scaffold core compared to existing allosteric RdRp inhibitors. Such workflows provide an 
alternative screening protocol alongside high-throughput screening campaigns and may 
therefore increase the structural diversity of hit compounds. Hence it may give rise to more 
choices when selecting compounds to progress to the next phase of drug discovery. Future 
work may include investigating methods to improve the hit rate of the virtual screening 
workflow. Such improvements may be achieved by incorporating biological data into the 
workflow, for example the information of which particular amino acids in the binding pocket 
is important for the protein-ligand interactions. Possible improvements to the consensus 
scoring method used in the processing of docking results may also be carried out. The 
assigning of equal weights to each scoring function is not ideal and methods that are able to 





multi-objective optimization method such as the Grey Relational Analysis 
356-358
 to assign 
calibrated weights to each scoring function may be an area of future studies. 
 
In the final part of the thesis, the Taguchi Method has been shown to be a possible 
alternative to the conventional approach of exploring the SAR around particular scaffolds. 
Instead of synthesizing all of the combinatorial compounds, it proposes only the most 
promising ones and thereafter predicts the most active compound within the combinatorial 
space. Clearly, it is a more systematic approach to selecting which compounds to synthesize. 
It is also more efficient since the number of compounds that need to be synthesized is 
significantly reduced. Future work may include applying the Taguchi Method to compound 
series that require higher arrays, i.e. more substitution sites with more R-group substituents at 
each site. The performance of the Taguchi Method could also be compared to other DoE 
methods such as Fractional Factorial and Response Surface Methodology.
359
 Also, the 
robustness of the Taguchi Method to the assignment of the R-group substituents to different 
levels should also be investigated. This is especially important for scenarios in which there 
are more than two R-group substituents at each substitution site.  
 
The selection and prioritization of compounds are at the core of medicinal chemistry 
efforts in drug discovery. As such, there is increasing recognition that this process should 
simultaneously take into account the balance of multiple properties present in a compound, 
e.g. potency, toxicity, permeability, selectivity and clearance. This is a significant departure 
from the previous paradigm of prioritizing compounds in turn, i.e. one property at a time. 
Indeed, a shift has already been made in this direction 
360-363
 and the future trend is towards 
the application of multi-objective optimization techniques for drug discovery. 
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APPENDIX 1: ENRICHMENT RESULTS 
Table S1.1 The top 10 PubChem-MACCS fingerprint keys/substructures selected for the respective datasets. 
 Rank 




















PubchemFP621 PubchemFP378 PubchemFP572 PubchemFP385 PubchemFP438 PubchemFP491 PubchemFP386 PubchemFP447 PubchemFP674 PubchemFP577 
EGFR Test 
Set 




















PubchemFP621 PubchemFP491 PubchemFP447 PubchemFP577 MACCSFP49 PubchemFP16 PubchemFP484 PubchemFP445 PubchemFP674 PubchemFP443 
SRC Test 
Set 




















MACCSFP49 PubchemFP261 PubchemFP258 PubchemFP372 PubchemFP385 PubchemFP491 PubchemFP445 PubchemFP577 PubchemFP16 PubchemFP403 
AKT1 Test 
Set 




















MACCSFP89 PubchemFP150 PubchemFP712 PubchemFP597 PubchemFP528 PubchemFP576 MACCSFP104 PubchemFP145 PubchemFP403 None 
PKCβ Test 
Set 




















PubchemFP621 PubchemFP379 PubchemFP530 PubchemFP145 PubchemFP435 PubchemFP357 PubchemFP16 PubchemFP596 PubchemFP521 PubchemFP482 
CDK2 
Test Set 




















PubchemFP373 PubchemFP674 PubchemFP372 PubchemFP435 PubchemFP445 PubchemFP491 PubchemFP379 MACCSFP62 PubchemFP577 PubchemFP636 
p38α Test 
Set 






Table S1.2 The cumulative percentage of potent compounds picked up (by PubChem-MACCS fingerprint keys) 
at each decile. 
 Decile 
 1 2 3 4 5 6 7 8 9 10 
EGFR Validation Set 1 49.7% 75.5% 85.2% 87.7% 89.0% 93.4% 100.0% 100.0% 100.0% 100.0% 
EGFR Validation Set 2 52.4% 78.0% 83.7% 87.2% 88.5% 97.8% 100.0% 100.0% 100.0% 100.0% 
EGFR Validation Set 3 52.3% 75.9% 85.1% 87.0% 87.6% 89.8% 100.0% 100.0% 100.0% 100.0% 
EGFR Validation Set 4 51.4% 78.5% 85.2% 86.8% 88.3% 89.6% 100.0% 100.0% 100.0% 100.0% 
EGFR Validation Set 5 52.4% 77.8% 85.4% 87.9% 88.6% 89.8% 100.0% 100.0% 100.0% 100.0% 
EGFR Test Set 52.4% 73.7% 84.3% 87.1% 87.8% 90.0% 100.0% 100.0% 100.0% 100.0% 
SRC Validation Set 1 60.8% 81.6% 88.5% 97.7% 99.5% 99.5% 100.0% 100.0% 100.0% 100.0% 
SRC Validation Set 2 56.2% 74.2% 84.3% 90.8% 97.2% 98.2% 100.0% 100.0% 100.0% 100.0% 
SRC Validation Set 3 65.4% 81.1% 91.7% 92.6% 94.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
SRC Validation Set 4 51.4% 75.2% 82.1% 94.0% 95.0% 97.2% 97.7% 99.5% 99.5% 100.0% 
SRC Validation Set 5 63.3% 77.1% 89.0% 94.0% 95.9% 96.3% 100.0% 100.0% 100.0% 100.0% 
SRC Test Set 64.5% 77.4% 86.6% 89.4% 97.2% 97.2% 97.2% 100.0% 100.0% 100.0% 
AKT1 Validation Set 1 96.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
AKT1 Validation Set 2 79.8% 91.3% 93.3% 93.3% 97.1% 97.1% 100.0% 100.0% 100.0% 100.0% 
AKT1 Validation Set 3 80.8% 95.2% 96.2% 96.2% 97.1% 97.1% 100.0% 100.0% 100.0% 100.0% 
AKT1 Validation Set 4 89.4% 95.2% 96.2% 97.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
AKT1 Validation Set 5 88.6% 95.2% 97.1% 97.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
AKT1 Test Set 80.6% 94.2% 94.2% 95.1% 97.1% 97.1% 100.0% 100.0% 100.0% 100.0% 
PKCβ Validation Set 1 56.1% 84.8% 86.4% 93.9% 95.5% 97.0% 97.0% 97.0% 100.0% 100.0% 
PKCβ Validation Set 2 59.1% 83.3% 89.4% 93.9% 97.0% 97.0% 98.5% 98.5% 100.0% 100.0% 
PKCβ Validation Set 3 54.5% 83.3% 86.4% 95.5% 98.5% 98.5% 98.5% 100.0% 100.0% 100.0% 
PKCβ Validation Set 4 84.8% 90.9% 93.9% 97.0% 98.5% 98.5% 100.0% 100.0% 100.0% 100.0% 
PKCβ Validation Set 5 63.6% 81.8% 89.4% 90.9% 93.9% 97.0% 97.0% 98.5% 98.5% 100.0% 
PKCβ Test Set 57.6% 78.8% 86.4% 90.9% 93.9% 95.5% 98.5% 100.0% 100.0% 100.0% 
CDK2 Validation Set 1 36.1% 52.6% 70.3% 88.0% 92.5% 93.6% 99.2% 100.0% 100.0% 100.0% 
CDK2 Validation Set 2 34.4% 50.9% 71.8% 88.3% 93.8% 95.2% 100.0% 100.0% 100.0% 100.0% 
CDK2 Validation Set 3 37.2% 56.9% 75.9% 89.1% 94.9% 97.8% 98.2% 100.0% 100.0% 100.0% 
CDK2 Validation Set 4 31.3% 54.1% 69.8% 86.6% 92.9% 96.3% 100.0% 100.0% 100.0% 100.0% 
CDK2 Validation Set 5 34.8% 53.8% 73.5% 92.4% 95.1% 96.6% 98.9% 100.0% 100.0% 100.0% 
CDK2 Test Set 33.2% 52.3% 72.1% 88.2% 93.1% 95.4% 100.0% 100.0% 100.0% 100.0% 
p38α Validation Set 1 36.3% 57.7% 70.3% 83.0% 89.9% 93.4% 98.4% 100.0% 100.0% 100.0% 
p38α Validation Set 2 28.5% 58.2% 68.7% 80.8% 89.2% 94.1% 98.8% 100.0% 100.0% 100.0% 
p38α Validation Set 3 29.5% 57.1% 70.2% 84.5% 90.4% 95.0% 97.8% 100.0% 100.0% 100.0% 
p38α Validation Set 4 25.2% 50.9% 66.1% 77.0% 88.2% 92.5% 97.8% 100.0% 100.0% 100.0% 
p38α Validation Set 5 30.8% 59.2% 64.7% 81.0% 86.1% 90.9% 97.3% 100.0% 100.0% 100.0% 
























































































































































































































































Figure S1.1 Enrichment curve of the five-fold cross validation and external validation. Each plot shows the fold 






Table S1.3 The top 10 Klekota-Roth fingerprint keys/substructures selected for the respective datasets. 
 Rank 
 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 
AKT1 Validation Set 1 KR1 KR298 KR296 KR1192 KR668 KR3402 KR3025 KR3926 None None 
AKT1 Validation Set 2 KR3640 KR3402 KR3882 KR1193 KR3750 None None None None None 
AKT1 Validation Set 3 KR1501 KR2976 KR2975 KR2548 KR3402 KR3025 KR1193 KR3926 None None 
AKT1 Validation Set 4 KR3402 KR3025 KR1193 KR3926 None None None None None None 
AKT1 Validation Set 5 KR3402 KR3025 KR1193 KR3926 None None None None None None 
AKT1 Test Set KR3402 KR3025 KR1193 KR3926 None None None None None None 
p38α Validation Set 1 KR3956 None None None None None None None None None 
p38α Validation Set 2 KR3956 None None None None None None None None None 
p38α Validation Set 3 KR2974 KR2975 KR4080 KR4330 KR3223 KR4079 KR296 KR3882 KR4331 KR3224 
p38α Validation Set 4 KR3956 None None None None None None None None None 
p38α Validation Set 5 KR3956 None None None None None None None None None 











APPENDIX 2: EXPERIMENTAL ACTIVITY DATA 
Table S2.1. IC50 values of test compounds on APL (NB4) cell line. 




APL cell line NB4 
1 Cyclohexanone H 4.50 ± 0.42 
2 Cyclohexanone 3OCH3, 4OH 2.12 ± 0.33 
3 Cyclohexanone 3OH, 4OCH3 1.23 ± 0.33 
4 Cyclohexanone 3OCH3, 4OCH3 4.01 ± 0.24 
5 Cyclohexanone 3OH, 4OH 2.79 ± 0.56 
6 Cyclohexanone 3H, 4OCH3 19.56 ± 1.53 
7 Cyclohexanone 3OCH3, 4H 6.24 ± 0.49 
8 Cyclohexanone 3H, 4OH 2.50 ± 0.11 
9 Cyclohexanone 3OH, 4H 0.98 ± 0.06 
10 Thiopyranone 3H, 4OCH3 17.19 ± 4.53 
11 Thiopyranone 3OCH3, 4H 2.51 ± 0.28 
12 Thiopyranone 3H, 4OH 2.52 ± 0.22 
13 Thiopyranone 3OH, 4H 0.51 ± 0.07 
14 Thiopyranone H 1.19 ± 0.23 
15 Thiopyranone 3OH, 4OH 4.71 ± 0.33 
16 Thiopyranone 3OCH3, 4OCH3 0.69 ± 0.02 
[a]
 
Mean of three or more independent experiments. 
 
